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Abstract 
 
 Polypharmacy (PP), often defined as the use of five or more medications, is 
highly prevalent in patients with cancer. As the quantity of medications for treating 
cancer and comorbid conditions in patients with cancer become more numerous and 
diverse, it is important to understand the various ways in which patient health and 
economic outcomes may be adversely affected by prescribed medications. The 
purpose of this dissertation was to investigate three distinct associations between PP 
and the lives of patients living with cancer by estimating how PP (1) affects health-
related quality of life (HRQoL), (2) is associated with healthcare expenditures, and (3) 
affects health complications (HCs). 
 
 Approximately 25% of cancer survivors, individuals who were diagnosed with 
cancer and are still alive, report a decreased quality of life related to physical 
problems, and 10% report a decreased quality of life related to emotional issues, 
compared to their noncancer counterparts (10% and 6%, respectively). Specifically, 
cancer survivors report more mobility issues, inferior health, higher psychological 
distress, and more mental health needs. There is scant published literature describing 
PP in contributing to these outcomes. This study was conducted to address this gap to 
better inform cancer survivors, care providers, and health policy decision makers. 
 
 Cancer was the sixth most expensive condition to treat in the United States 
(US) in 2015. Most cancers are estimated to have a decreasing incidence and 
 
 
increasing survival rate for the foreseeable future. A decreasing incidence may cause 
overall cancer-related expenditures to decline over time, but the prevalence of cancer 
coupled with the aging of the US population will result in an increase in the number of 
cancer survivors. Thus, expenditures during treatment through end of life are expected 
to continue to increase in coming years, as cancer survivors are estimated to increase 
from 15.5 million in 2016, to 26.1 million by 2040. 
 
 Common cancer-related ailments such as pain, emesis, depression, venous 
thrombosis, and seizures can require prescription medications. With additional 
medications arises the risk for a health complication (HC). A HC, for the purposes of 
this study, is defined as an adverse health problem related to a drug, including adverse 
drug reactions, worsening of disease symptoms, falls, or overdoses. Although many 
HCs are preventable, they represent approximately 125,000 hospitalizations, over 3.5 
million physician office visits, and an estimated 1 million emergency department visits 
each year in the general population. Previously identified risk factors for HCs in 
people with cancer, depending on the type of cancer, include PP, advanced stage of 
cancer, higher comorbidity, gender (for colorectal cancer), older age, and prior ER 
visits or hospitalizations. 
 
 The purpose of the studies in this dissertation was to advance understanding of 
the role of PP on health and economic outcomes among people with cancer. We 
examined two data sources: (1) a large national survey database for manuscripts 1 and 
 
 
2, and (2) a large, commercial claims database of privately-insured individuals for 
manuscript 3; both of which included United States (US) populations.  
 
Manuscript 1: The intent of this manuscript was to evaluate if an association 
exists between PP and HRQoL in cancer survivors in the US. The analysis used self-
reported answers to questions about various demographic and clinical information 
captured in the Medical Expenditures Panel Survey (MEPS) database for even years 
2008-2014. Respondents, who stated they were told that they had cancer, answered 
questions from the SF-12v2 about their physical and mental health, which were 
converted to the HRQoL measures PCS and MCS used for this analysis. This study 
focused on comparing cancer survivors, defined as having ≥ 5 prescribed medication 
classes in the year of the interview, with those with less than 5 medication classes. 
Differences among types of cancer were also explored in both descriptive and 
regression analyses. This study hypothesized that PP would lead to lower HRQoL as 
compared to patients not having PP. Of 10.1 million survivors per year included in this 
study, 45% were defined as having PP. We used ordinary least squares (OLS) 
regression to estimate that PP was associated with a statistically and clinically 
significant decrease in PCS scores among cancer survivors by 3.75 points. However, 
PP was not associated with a significant decrease in MCS scores. As such, PP should 
be analyzed closely in cancer survivors to ensure the best possible HRQoL.  
  
Manuscript 2: Healthcare expenditures are increasing in the US, and that is 
especially true for patients living with cancer. The objective of this manuscript was to 
 
 
determine if PP was associated with increased direct health care expenditures, and if 
differences in expenditure exist according to cancer type or setting of care. This aim 
was accomplished by using the same years and source of data as Manuscript 1, while 
modeling expenditure as a dependent variable. We hypothesized that PP was 
associated with increased health expenditures in total, by type of cancer and by setting 
of care. We used OLS regression with log transformed expenditures to obtain 
estimates of association between PP and increased health expenditures controlling for 
various demographic, socioeconomic, and clinical variables. PP was present in 43.9% 
of the 10.6 million (per year) cancer survivors in the study. PP was associated with a 
mean annual adjusted healthcare expenditure per cancer survivor of $13,266 (SD 
$3,766), which was significantly higher than those without PP $8,573 (SD 5,082, p-
value <.0001). Cancer survivors with PP accounted for 70% of total healthcare 
expenditures, yet only comprised 43.9% of the population.  
 
 Manuscript 3: This study focused on newly diagnosed patients with breast, 
prostate, colorectal, or lung cancer and investigated if an association exists between 
PP and nonfatal health complications (HCs). The data source used was Optum 
Clinformatics® DataMart (Optum, Eden Prairie, MN, USA), years 2010-2015. The 
database contains de-identified claims information with medical, prescription drug, 
enrollment, and other data tables. PP was measured as the use of ≥ 5 prescribed 
medication classes in the quarter (3 months) following incident cancer diagnosis. HCs 
was the dependent variable in the analysis and included a range of medical conditions 
known to be caused or worsened by effects of medications including falls, fractures, 
 
 
gastrointestinal bleeding, and delirium. Descriptive and logistic regression analyses 
were conducted to assess any associations between PP and HCs in a multivariable 
framework. This study hypothesized that HCs would occur more frequently among 
patients with PP than those without PP.  In the primary analysis using multivariable 
LR modeling, PP was associated with 31% increased odds (adjusted odds ratio: aOR) 
of having ≥ 1 HCs, controlling for age, region, type of cancer, comorbidities, radiation 
and chemotherapy treatments. PP was significantly associated with a higher risk of 
having ≥ 1 HC in each cancer type (aOR: breast 1.37, 95% CI: 1.31-1.42; prostate 
1.27, CI: 1.22-1.32; colorectal 1.26, CI: 1.16-1.36; lung 1.25, CI:  1.11-1.40). Active 
chemotherapy was associated with significantly increased odds of ≥ 1 HC in colorectal 
(aOR: 1.35, CI: 1.21-1.50) and lung (aOR: 1.33, CI: 1.15-1.54) cancers, but not 
significantly associated with breast or prostate cancers. Newly diagnosed patients with 
breast, prostate, colorectal, or lung cancer were all at a higher risk of having ≥ 1 HCs 
if defined as having PP compared to those without PP. Active chemotherapy treatment 
was associated with increased risk of HCs in colorectal and lung cancer patients, but 
not in breast or prostate cancer patients. 
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Preface 
 
The manuscript format was used to examine three distinct associations 
between polypharmacy (PP), often defined as the use of multiple medications, and the 
lives of patients living with cancer by estimating how PP (1) affects health-related 
quality of life (HRQoL), (2) is associated with healthcare expenditures, and (3) affects 
health complications (HCs). I hope this work is impactful. 
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1.1 Abstract 
 
PURPOSE: Polypharmacy (PP) is present in many cancer survivors and may lead to 
lowered health-related quality of life (HRQoL). The objective of this study was to 
evaluate the association between PP and HRQoL among non-institutionalized cancer 
survivors living in the United States (US). 
METHODS: A cross-sectional analysis of Medical Expenditure Panel Survey 
(MEPS), a set of surveys of households, their medical providers and employers 
throughout the US was conducted. Our analytic sample included all adult patients with 
a clinical classification code for cancer, during even years 2008-2014. PP was defined 
as reported use of five or more therapeutic classes of prescription medications. The 
MEPS measured HRQoL using the Short Form 12-Item Health Survey Version 2 (SF-
12v2) Physical Component Summary (PCS) and Mental Component Summary (MCS) 
scores. Ordinary least squares regression was used to assess associations between PP 
and HRQoL controlling for various demographic, socioeconomic, and clinical factors. 
RESULTS: An estimated 10.1 million cancer survivors per calendar year were 
analyzed in this study. Cancer survivors were mostly white (81.8%), female (56.0%), 
and under the age of 65 (51.6%). Female breast (17.2%), prostate (13.7%), and 
melanoma (7.3%) were the most prevalent cancer types. PP was present among 44.4% 
of cancer survivors. After adjusting for covariates, the mean PCS score for survivors 
with PP was 35.8 points, which was significantly lower compared to those without PP 
(39.5) by 3.7 points (p-value <.0001). Conversely, PP was not significantly associated 
with differences in the mean MCS score compared to survivors without PP (44.9 vs. 
3 
 
45.4, respectively) in multivariable regression analyses adjusting for demographic, 
socioeconomic, and clinical variables. 
CONCLUSIONS: Cancer survivors with PP accounted for approximately 45% of the 
analyzed sample and had a significantly lower PCS score than their counterparts 
without PP. 
IMPLICATIONS FOR CANCER SURVIVORS: PP should be examined closely 
by cancer survivors because of increased associations with poorer physical domain of 
quality of life. 
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1.2 Introduction 
 
Approximately 25% of cancer survivors, individuals who were diagnosed with 
cancer and are still alive, report a decreased quality of life related to physical problems 
and 10% report a decreased quality of life related to emotional issues compared to 
their noncancer counterparts (10% and 6%, respectively).1 Specifically, cancer 
survivors report more mobility issues, inferior health, higher psychological distress, 
and more mental health needs.1 They also worry about recurrence of their malignancy, 
new types of neoplasms,2 and the possible long-term damage their cancer treatment 
may cause.3 These concerns are additional to normal apprehensions about aging and 
the occurrence of comorbidities.4 Approximately 70% of cancer survivors have one or 
more comorbidities.5 Many observational studies have reported that cancer patients 
have poorer survival if they have comorbidities.6   
 
Cancer has a systemic impact on both body and mind.1 Treating these impacts 
usually leads to greater use of prescription medications.7,8 Cancer patients may have 
underlying comorbid conditions prior to their cancer diagnosis requiring medication 
therapy. As the number of medications increases with medication therapy for cancer, 
concurrent multiple medications treating both comorbid conditions and cancer may 
lead to polypharmacy (PP). A cross-sectional study using the Medical Expenditure 
Panel Survey (MEPS) database, estimated the prevalence of PP, defined by the study 
as ≥ 5 unique prescription medications, to be 64% among cancer survivors, compared 
to 51.5% in the non-cancer control group.5 The study found that the median number of 
5 
 
unique prescription medications was 6 for cancer survivors, but only 4 for noncancer 
controls, despite the majority (55%) of survivors having been diagnosed ≥ 5 years 
previously.5   
 
As cancer survivors receive an increased number of concomitant medications, 
they become at an increased risk of dangerous adverse event occurrence.9 Concerns 
about PP arise from certain harmful situations, such as when unforeseen or unintended 
drug effects and drug-drug interactions result in health complications.10 Short-term, 
long-term, and late effects of cancer treatments,11 related, in-part, to prescribed 
chemotherapy regimens may also negatively impact cancer survivors.12 Treatment 
effects include a wide variety of impacts to organs, tissues, body development, 
growth, mood, feelings, actions, thinking, learning, memory, social and psychological 
adjustment, and risk of second cancers.12 Treating these late effects to alleviate 
discomfort can require additional medications such as analgesics for pain,13 and 
corticosteroids to help breathe normally,14 among other drugs for symptoms which 
may decrease health-related quality of life (HRQoL).1   
 
A retrospective cohort study of adults (21 years and older) with arthritis 
conducted using the MEPS, found that PP was associated with significantly lower 
physical HRQoL scores.15 Based on this evidence and the negative impacts of cancer 
on HRQoL, investigating the relationship between PP and HRQoL in the cancer 
survivor population was warranted. The objective of this study was to evaluate this 
6 
 
association between PP and HRQoL among cancer survivors living in the US using a 
nationally representative survey database. 
  
7 
 
1.3 Methods 
 
Study design and data source 
We used a multi-year cross-sectional study design to analyze the MEPS, a 
publicly available database which contains survey questionnaire responses of de-
identified non-institutionalized persons and their families (households), their medical 
providers, and employers in the US.16 The MEPS includes five interviews over the 
course of 2 calendar years conducted via computer assisted personal interviewing 
(CAPI). The multiple interviews allow for (1) analyzing how people’s healthcare 
changes over time and (2) minimizing recall bias.17 The MEPS also permits weighting 
of the data to produce nationally representative estimates of the US population for 
various healthcare analyses (e.g. expenditures, utilization of resources, insurance 
plans).16   
 
Two major components are included in the MEPS: household and insurance.16 
We selected the longitudinal, medical conditions, and prescribed medicines files from 
the household component for this study and linked them through a unique identifier 
for each individual.16 We first used the medical conditions file to find individuals who 
reported having been diagnosed with cancer by using the cancer specific clinical 
classification codes; which are defined using the Clinical Classification Software 
provided by the Agency for Healthcare Research and Quality (AHRQ) which clusters 
diagnoses codes into a manageable number of categories.18 Respondents were defined 
as cancer survivors during the interview process if they answered affirmatively to the 
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question “Have you ever been told by a doctor or other health professional that you 
had cancer or a malignancy of any kind?” Those who confirmed having, or had, 
cancer were asked what type of cancer and their age at diagnosis.19 We also used 
clinical classification codes and the International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) codes to identify concurrent chronic 
conditions. Further details regarding MEPS have been described elsewhere.16  
 
Sample selection 
We combined the MEPS data for years 2008, 2010, 2012, and 2014 for our 
analyses. In the MEPS process of interviewing, individuals are followed for two years, 
therefore we selected even years to avoid including repeated observations. 
Respondents with cancer other than nonmelanoma skin cancer, who were at least 18 
years of age at the time of response, were included in this study. We excluded those 
who had missing, negative, or zero person-level sample weights. To limit the effect of 
multiple cancers on the estimated relationship between PP and HRQoL, individuals 
were excluded if they had more than one type of cancer.19 We also excluded those 
who died during the calendar year due to possible inflated prescription counts during 
end-of-life care and the possible effect terminal cancer would have on HRQoL scores. 
In one retrospective cross-sectional study of 4,252 hospice patients across 11 states in 
the US, 35% of whom had cancer, the mean number of prescriptions was 15.20 Figure 
1 shows a flowchart of inclusion and exclusion criteria. 
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Measures  
Dependent variable 
Health-related quality of life  
We chose the Physical Component Summary (PCS) and Mental Component 
Summary (MCS) scores, calculated from the Medical Outcomes Study Short-Form 12 
Health Survey Version 2 (SF-12v2) as our dependent variables. The SF-12v2 is 
collected as part of the MEPS during rounds 2 and 4 of the survey to measure 
HRQoL.21 Included in the survey for PCS are questions which focus on the general 
health, mobility activity, limitations on activities or work, vitality, and pain.21 The 
MCS has questions regarding whether depression and anxiety have an impact on 
accomplishments or work, mental health regarding feelings of calm and peacefulness, 
and social activities limitations.21 PCS and MCS scores range from 0 to 100 and are 
calibrated so that 50 is the mean score with a standard deviation of 10 for the general 
US population.22 For both PCS and MCS scores, a higher score indicates a better 
HRQoL. The SF-12v2 has been proven as both reliable and valid for measuring 
HRQoL in the cancer survivor population using the MEPS.23   
 
Key independent variable 
Polypharmacy 
A consensus definition of PP does not currently exist.24 Some investigators 
have measured PP by individual drug or classes of medications.15,24 
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The MEPS provides a prescriptions file with therapeutic medication class 
information which are linked to the Multum Lexicon database for analysis.25 We used 
these therapeutic class details to determine the maximum number of classes of 
prescription medications the individuals were prescribed in one of the rounds that 
coincided with our study years. We defined PP as using ≥ 5 therapeutic classes of 
medications in one of the rounds of interviews, which is consistent with other 
definitions in published literature.15,26   
  
Covariates 
Demographic variables included age group based on quartile analysis, sex, 
race/ethnicity, geographic region, and marital status. 
 
Socioeconomic variables included income, insurance status, and level of 
education. A person’s income level was categorized as low, middle, or high; where 
low indicates a person is below 200% above the poverty line, middle indicates 200% 
to 400% above the poverty line, and high indicates 400% or greater income than the 
poverty line. Insurance was categorized as privately-insured, uninsured, or publicly-
insured. Level of education was classified into 3 groups: less than high school (i.e. did 
not graduate), high school graduate, and some college (must not have graduated to be 
included). 
 
Clinical variables included type of cancer, time since cancer diagnosis, select 
chronic conditions common in cancer survivors, and number of total healthcare 
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encounters. We classified cancer into several groups based on logical groupings or 
sample size (if a specific type of cancer had too small a count to be its own subclass). 
The cancer type groups were the following: breast, prostate and other male genitals 
(included testicular cancer), cervical and other female genitals (included uterine, 
ovarian, other female cancers), colon and other gastrointestinal (GI) (stomach, liver, 
pancreas, and other GI cancers), melanoma, leukemias/lymphomas, and other or 
unspecified (included lung) (Appendix A). We created a variable for time (years) since 
cancer diagnosis by subtracting the person’s reported age at diagnosis from their 
reported age at the time of the survey because it was found to be a significant indicator 
of HRQoL among certain cancer groups.19 For patients who could not remember, or 
otherwise did not provide a response for age at diagnosis, we used a statistical multiple 
imputation procedure to assign time since cancer diagnosis.27 Multiple imputation is 
an iterative process which uses the distribution of the observed data to estimate the 
true value of the missing variable. Values produced were used in regression analysis 
with the results pooled through statistical software to make valid inferences about the 
parameters and standard errors. To fit the structure of the variable, we used a 
minimum value of 0 (years) and maximum value of 85 (years). We achieved a relative 
efficiency of 99.0% and 99.1% with 25 imputations for our PCS and MCS models, 
respectively.28 Comorbidities were selected from a list of priority health physical 
conditions provided by the MEPS and included the following: arthritis, chronic 
obstructive pulmonary disease, diabetes, and heart disease/cardiovascular ailments.26 
We chose these comorbidities based on MEPS’ recognition that they are more 
prevalent, expensive, or especially relevant to healthcare policy as well as their impact 
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on physical functioning.29 To assess the influence of mental health conditions in our 
study population, we selected mood disorders (bipolar and depression) and anxiety 
disorders, using the MEPS designated mental health disorders clinical classification 
codes to identify these conditions for each patient (Appendix B). We dichotomized 
these conditions as either present (1) or absent (0). Healthcare encounters were defined 
as total provider or outpatient visits obtained from the household files and categorized 
based on quartiles into the following groups: 0-4, 5-9, 10-19, and ≥ 20 visits.  
 
Statistical analysis 
We used chi-square tests to determine the statistical significance of differences 
in presence or absence of PP for each independent variable (IV) according to statistical 
significance (p-value <0.05). Analysis of variance (ANOVA) was used to assess the 
relationship between the various levels of the categorical variables with the dependent 
variables (DVs), where p-values <0.05 indicated a significant relationship. To estimate 
the mean scores for PCS between those with or without PP, T tests were used 
controlling for significant covariates. Mean PCS and MCS score differences by PP 
with 95% confidence intervals were calculated as part of the T tests. 
 
Univariate OLS regression models were used to test the significance of 
association for each covariate by using the magnitude of the F value and p-value 
statistic; whereby, significance of p-value < 0.10 resulted in the variable being 
included in the multivariable OLS regression modeling process. If the variable was 
significantly associated with both PP and PCS/MCS then they were held for further 
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analysis in the modeling process. To ensure the IVs were not correlated with one 
another the variance inflation factor (VIF), variance decomposition proportions 
(VDFs), and condition indices (CNIs) options provided in the SAS procedural 
software were used. If covariates had a VIF of ≥ 5.0, VDFs ≥ 0.5 (for two variables), 
or CNI ≥ 30, collinearity would have been assumed and removal of one of the IVs 
would have occurred.30 However, neither the PCS nor MCS models’ variables reached 
these thresholds.  
 
Multivariable OLS regression was used to evaluate the association between PP 
and PCS/MCS scores controlling for all significant covariates. The ability to predict 
physical or mental well-being by a covariate was judged by its p-value significance 
level (p-value ≤ 0.05) in the multivariable modeling process. In the model building 
process, covariates were included sequentially based on p-value and F-value 
significance. If two covariates had the same p-value (e.g. <.0001), then the covariate 
with the largest F-value was considered more significantly associated with the DV. 
The adjusted model’s overall fit was measured using the coefficient of multiple 
determination adjusted R2. When adding covariates to the model no longer produced a 
better fitting model (higher adjusted R2 = better fit), a manual stepwise process was 
implemented. This process involved removing a covariate which was significant in 
univariate analysis, with a high F-value, but when added to the multivariable model 
became insignificant. This stepwise technique was used until only significant 
covariates were left. Parameter (beta, β) estimates with standard errors (SE) were used 
to determine the direction and magnitude of association between PP and PCS/MCS 
14 
 
scores. Parameter direction and magnitude were evaluated at each iteration of the 
model building process to verify no multicollinearity existed, which would have been 
evidenced by a large change in magnitude or direction, and/or a large jump in adjusted 
R2 despite a variable not being significantly associated with the DV.  
 
Due to the complexity of the survey design used in the MEPS; stratification, 
clustering, and weighting were performed to control for clustering and unequal 
probability design.31 Significance tests were all performed at the α = 0.05 level. All 
analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). 
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1.4 Results 
 
The study population consisted of an unweighted total of 3,281 adult cancer 
survivors (Table 1). This sample represented approximately 10.1 million non-
institutionalized cancer survivors per calendar year living in the US. Weighted 
percentages per annum for the 3 most prevalent specified types of cancer in the study 
were breast (17.2%), prostate (13.7%), and melanoma (7.3%) with the largest single 
group being other/unspecified (44.8%). Table 2 includes the proportions of all 
independent variables in total by PP or no PP. The sex of the cancer survivors was the 
only variable without significant difference between groups for those with or without 
PP (p=0.4899). Older survivors (≥75) had PP in greater proportion (60.9%) than 
younger survivors (18-49: 18.5%). Survivors of cervical cancer had the lowest 
percentage of PP (38.1%); while survivors of leukemias and lymphomas had the 
highest (50.1%). Approximately 60% or more of the survivors with PP also had 
chronic conditions (arthritis 59.7%; COPD 69.7%; heart conditions 63.8%; diabetes 
77.6%; anxiety 66.3%; mood 67.3%) which was significantly different than those 
without PP (p-value <.0001). Of the cancer survivors included in this study, 1,460 
(weighted N=4,471,359; 44.4%) reported use of ≥ 5 therapeutic classes of prescribed 
medications. Table 3 highlights that the 10 most frequently reported therapeutic 
classes of prescribed medications were very similar for those with PP and those 
without. Between those with PP and those without PP, only 6 therapeutic classes 
differed in total. In the PP group, the patients reported to be prescribed diuretics, 
antidiabetic agents, and anticonvulsants more frequently compared to dermatological 
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agents, antihypertensive combinations, and macrolide derivatives in the without PP 
groups. The 10 most commonly prescribed therapeutic classes for those with PP made 
up 42.8%, whereas those without PP was 48.3% of the total number of prescribed 
therapies. 
 
Adjusted mean PCS and MCS with mean differences by PP 
Significantly lower mean PCS scores existed for all survivors with PP except 
those with prostate cancer (Figure 2). Survivors of cervical and other female genital 
cancers with PP had the lowest mean PCS score difference of 6.8 points [95% CI: 2.4-
11.3], or 17.9%, compared to women without PP (31.1 [26.4-35.7] versus 37.9 [33.4-
42.5], p-value 0.0027). Colon and other GI cancers had a similarly low mean PCS 
score difference of 6.7 points [2.7-10.6], or 15.6%, in those with PP compared to those 
without PP (35.8 [31.4-40.3] versus 42.5 [38.2-46.8], p-value 0.0012). Adjusted mean 
MCS score differences by PP were not statistically significant for any individual type 
of cancer. Adjusted mean PCS and MCS, as well as mean difference significance by 
cancer type, with or without PP are depicted in Figure 2. 
 
Associations between PP and PCS/MCS scores 
Mean adjusted PCS scores for those with PP (35.76 [95% Confidence Interval: 
34.30-37.23]) were significantly associated (p-value <.0001) with lower PCS scores 
by 3.75 [2.63-4.87] points compared to those without PP (39.51 [37.97-41.06]) when 
controlling for all variables associated with both PP and MCS/PCS in the model 
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(Table 4). No type of cancer was significantly different from their referent group of 
leukemias and lymphomas for the PCS multivariable OLS model.  
 
Table 4 provides the findings from the unadjusted and adjusted OLS regression 
models to determine the significance of association between PP and PCS, controlling 
for all investigated variables which had at least one group significantly different from 
their referent group. Patients who were aged ≥ 75 had mean PCS scores which were 
significantly lower than the youngest age group (18-34 years) by more than 3 points 
(β= -3.35 SE 0.71 p-value <.0001) when controlling for all other significant variables 
in the model. Survivors with arthritis (β= -4.76 SE 0.50 p-value <.0001), COPD (β= -
4.36 SE 0.67 p-value <.0001), diabetes (β= -2.83 SE 0.62 p-value <.0001), and heart 
conditions (β= -2.05 SE 0.53 p-value= 0.0001) had PCS scores significantly lower 
compared to survivors without those comorbid conditions. Individuals with ≥ 20 
healthcare encounters had PCS scores nearly 4 points lower than those with < 5 
encounters (β= -3.71 SE 0.62 p-value <.0001).  
 
In the multivariable regression model for MCS, mean MCS scores for those 
with PP (44.90 [43.6-46.2]) were not significantly different than survivors without PP 
(45.41 [44.1-46.8]), having a mean difference of 0.51 points lower ([0.49-1.51], p-
value= 0.3145), when controlling for all significant variables (Table 5). When 
controlling for significant variables in the OLS model, colon or other type of GI 
cancer was the only type of cancer significantly associated with MCS scores. The 
scores for those with colon or other type of GI cancer were approximately 2.5 points 
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lower than patients with leukemia or lymphoma (β= -2.34 SE 1.13 p-value= 0.0381). 
This 2.5-point difference represents a clinically meaningful difference in physical 
health from leukemia or lymphoma. Arthritis (β= -1.78 SE 0.41 p-value <.0001), 
anxiety (β= -2.98 SE 0.67 p-value <.0001), and mood disorders (β= -8.08 SE 0.67 p-
value <.0001) were associated with significantly lower MCS scores in adjusted 
analysis. Individuals with the lowest level of income had significantly lower MCS 
scores compared to those with the highest income by over 3 points (β= -3.25 SE 0.53 
p-value <.0001). Advanced age was associated with better MCS scores (50-64: β= 
1.35 SE 0.58 p-value= 0.0196; 65-74: β= 3.93 SE 0.69 p-value= <.0001; and ≥ 75: β= 
3.86 SE 0.71 p-value <.0001) compared to those 18-49 years old. Gender, race, 
marital status, region, education, number of healthcare encounters, COPD, diabetes, 
heart conditions, and time since cancer diagnosis were not significantly associated 
with MCS. 
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1.5 Discussion 
 
Our study contributes to the literature by being the only research, to the 
authors’ knowledge, examining the association between PP and HRQoL among adult 
cancer survivors in the US using nationally representative survey data. The study 
findings suggest that PP is associated with lower PCS scores by approximately 4 
points among adult cancer survivors in the US. We were not surprised by these results 
since management of chronic conditions among cancer survivors often requires 
multiple prescription medications including nonsteroidal anti-inflammatory drugs, 
benzodiazepines, antidepressants, and opioids, which often affect major organ 
systems.5  
 
Polypharmacy 
We found that nearly half (44.4%) of cancer survivors were prescribed ≥ 5 
distinct therapeutic classes of medications, thus were classified as having PP 
according to our definition. We consider this to be a conservative estimate of the true 
number of medications a patient was taking, as we did not count individual 
medications, for which patients could be using multiple medications from the same 
therapeutic class. In a systematic review of definitions for PP, 80.4% of 138 articles 
had a numerical value for the definition, 10.9% had numerical along with duration of 
therapy or healthcare setting, and 8.7% had descriptive definitions.24 The outcome of 
the systematic review was that the most commonly used definition for PP was ≥ 5 
daily prescription medications (46.4% of 110 articles meeting final inclusion 
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criteria).24 In a recently published survey study of 385 cancer survivors aged 70 or 
older, where the researchers were evaluating ranges of PP cut-points to a range of 
adverse events (falls, frailty) determined that using ≥ 5 medications concomitantly is 
reasonable for identifying at-risk patients.32 Murphy et al. examined individual 
medication counts among cancer survivors using the MEPS and found that 
approximately 64% of cancer survivors were taking ≥ 5 distinct medications 
concomitantly and had more physical limitation in adults 18 years and older.5 
However, their study did not look at mental health conditions or PCS/MCS as 
outcomes.  
 
High pill burden has been associated with increased use of inappropriate 
medication, thus increasing the risk of adverse outcomes.33 In a medical chart review 
of 244 cancer patients aged ≥70 years receiving chemotherapy, 39% of severe 
potential drug interactions involved chemotherapeutic agents.34 Additionally, the 
authors found that cancer patients’ risk of a potential drug interaction increases with 
each additional medication, up to 100% when 8 or more medications were being taken 
concomitantly.34 These risk estimates are higher than those reported in noncancer 
populations.34 However, not all PP can be considered inappropriate, as multiple 
medication use does occur commonly in cancer survivors and may be the result of 
appropriately treating multiple conditions. A closer look at the root causes should be 
undertaken to try to eliminate excessive risks of inappropriate PP, such as lack of 
integrated and coordinated care, and possible contraindicated drug-drug interactions, 
which may lead to adverse events.35 Conversely, not addressing adverse situations 
21 
 
requiring medications in a timely manner may lead to avoidable complications.  
However, this study was not intended to address appropriateness of prescribed 
medications and requires further investigation in the future. 
 
PCS  
Minimum clinically significant differences using the SF-12v2 range from 2-5 
points from the population mean of 50.36,37 The difference in the adjusted analysis was 
3.75 points, which met the lower bound of minimum clinically significant threshold. 
This difference of 3.75 points represents the change in mean score of PCS with a one-
unit change in PP (or a person switching from no PP to PP). Meaning that for someone 
in the general population with a PCS score of 50 and without PP, reaching the PP 
threshold of ≥ 5 unique classes of prescribed medications would be associated with 
having a worse PCS score by 3.75 points and be a proxy for worse physical domain of 
HRQoL.  
 
We did not find any published study which evaluated the association between 
PP and HRQoL in cancer survivors; however, a study had reported that cancer 
survivors were more likely to have physical limitations (29.0% vs. 21.6%), and worse 
overall health status than their noncancer counterparts (29.7% vs. 18.4%, 
respectively).5 In this study, we found PP was associated with worse PCS scores, after 
adjusting for comorbidity and age, among other covariates. As PCS is derived from 
questions about both general health and physical specific, it is possible that PP 
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decreases only specific areas covered by the PCS summary score. However, individual 
items were not analyzed in this analysis. 
 
MCS 
PP was not significantly associated with changes in MCS scores in cancer 
survivors compared to those without PP in our multivariable analyses, regarding 
statistical or clinically meaningful differences. Colorectal cancer was the only type of 
cancer which had a statistically and clinically meaningful difference in reported 
mental and emotional health by more than 2 points compared to patients with 
leukemia or lymphoma. According to LeMasters et al., who conducted a retrospective 
cross-sectional analysis using the Behavioral Risk Factor Surveillance System 
(BRFSS) survey, female colorectal cancer survivors have a significantly increased 
number of days as perceived bad mental health in the past month compared to 
matched noncancer controls.38 In a US population-based study, no difference was 
found in quality of life scores between women with cervical cancer versus those 
without.39 In our study, cervical cancer was not significantly associated with poorer 
PCS or MCS scores compared to leukemias and lymphomas.   
 
Previous research has shown significant associations among the covariates 
included in this study, which was our basis for including them. For example, Weaver 
et al., using the 2010 National Health Interview Survey, found that among 1,822 adult 
cancer survivors who responded to the PROMIS Global 10, a 10-item patient-reported 
outcomes survey, lower education and > 1 comorbidity were independently associated 
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with poor physical HRQoL.1 Also, among their findings and consistent with ours is 
that lower socioeconomic status was associated with poorer physical and mental 
health. Weaver et al. also found that younger age was associated with poorer mental 
health. Lastly, the Weaver et al. study found no differences among races/ethnicities for 
either physical or mental health and measurements of quality of life, a finding similar 
to what we found in multivariable analysis.1 In a study by Wang et al. conducted using 
the MEPS data, of 3,610 cancer survivors, the prevalence of each cancer type was 
similar to this study where 20.1% had breast, 15.0% had prostate, and 8.4% had 
melanoma.19 
 
PP in cancer survivors has been a concern for many years and this study 
confirms that use of multiple medications is still highly prevalent and warrants further 
attention in all cancer survivors. More consideration should be paid to continuity of 
care for cancer survivors to ensure appropriate medication use and non-medication 
management for chronic conditions. The study findings support the need for future 
research aimed at identifying the classes of prescription medications and the clinically 
significant drug-drug interactions that may cause survivors to report decreased 
physical QoL measured by PCS scores. Therefore, healthcare providers should 
evaluate the benefits and harms of prescribing multiple medications for cancer 
survivors. 
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1.6 Limitations 
 
Some limitations exist due to the nature of the data source. As the MEPS has a 
survey design depending on a person’s ability to remember various life events, 
responses are subject to recall bias. Also, the MEPS does not capture information on 
stage or severity of cancer which affects both PP and HRQoL, and so we could not 
adjust for these variables in our analyses. PP was not assessed for association with 
responses to specific mental or physical health states from the SF12-v2 since we used 
the summarized scoring totals for PCS and MCS; therefore, we cannot allude to any 
specific physical or mental functioning that may have been impacted by PP. Despite 
controlling for various comorbidities, severity of those illnesses could not be captured. 
We cannot make assumptions as to a causal effect that the cancer treatment, or the 
cancer itself, may have had on specific chronic conditions. 
 
As we evaluated the association between PP and HRQoL among cancer 
survivors by therapeutic class, some information may have been lost due to multiple 
drugs being used within the same class. Also, because this was cross-sectional, we 
cannot determine if an individual’s PCS or MCS scores changed over time with the 
addition or subtraction of medications. As PP is a proxy for measure of disease 
burden, it is likely that survivors were appropriately taking multiple medications to 
help address comorbid conditions rather than their comorbid conditions were due to 
taking so many medications. However, this paper’s intent was not to address 
appropriate versus inappropriate PP, hence further research is needed to better 
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understand PP’s impact on HRQoL. Though the association between cancer and PP 
has been reported previously,5 to our knowledge, no study had evaluated how PP is 
associated with HRQoL among adult cancer survivors in the US. 
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1.7 Conclusion 
 
In this cross-sectional study of community-dwelling cancer survivors in the 
US, PP was associated with lower PCS scores in certain types of cancer and those with 
higher comorbidity burden. Cancer survivors, their support system, providers, and all 
other pertinent stakeholders should have a vested interest in understanding how PP 
impacts the survivors’ lives to maximize HRQoL. PP should be examined closely by 
cancer survivors because of possible increased associations with poorer physical 
domain of quality of life. 
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Figure 1. Selection of Patients for Analyses of Prevalence of Polypharmacy in Adult Cancer 
Survivors (≥ 18 years) (2008, 2010, 2012, 2014), unweighted. 
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3,281 (57.9%) Adult Cancer 
Survivors in Study Sample  
5,664 Adults who had been 
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identified from interview years 2008, 
2010, 2012, 2014 
5,551 (98.0%) All cancer survivors 
with a valid person weight 
426 (11.5%) Excluded patients who 
had an invalid  PCS or MCS score 
(190; 5.1%), missing age (112; 
3.0%), < 18 years (70; 1.9%), died in 
round (53; 1.4%), or age at diagnosis 
was > current age (1; <0.1%).  
113 (2.0%) Excluded patients with 
zero person-weight information. 
1,844 (33.2%) Excluded patients 
with nonmelanoma skin cancer 
(1,183; 21.3%) or more than one type 
of cancer diagnosis (659; 11.9%); 
men with breast cancer (2; <0.1%).  
1,821 (55.5%)  
No Polypharmacy 
 
1,460 (44.5%) 
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Table 1. Distribution of Cancer Diagnoses in Adult Cancer Survivors (≥ 18 years) (2008, 2010, 
2012, 2014) of Interest Available in MEPS. 
Type of Cancer N (%), weighted 
Breast  1,730,969 (17.2%) 
Prostate and other male genital 1,382,904 (13.7%) 
Cervical and other female genital 594,733 (5.9%) 
Colon and other GI 644,921 (6.4%) 
Melanoma 731,028 (7.3%) 
Leukemias and lymphomas 467,401 (4.6%) 
Other / unspecified  4,524,103 (44.9%) 
Total 10,076,059 (100.0%) 
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Table 2. Demographic and Clinical Characteristics of Adult (≥ 18 years) Cancer Survivors (N= 
10,076,059) with Cancer Diagnoses of Interest 2008, 2010, 2012, 2014, Weighted n (%).  
Demographic and Clinical 
Characteristics  No Polypharmacy Polypharmacy p-valuee 
Total n= 5,604,700 (55.6%) n= 4,471,359 (44.4%)  
Age group (years)a <.0001 
     18-49  1,667,385 (81.5)    377,514 (18.5)  
     50-64 1,881,319 (59.6) 1,277,488 (40.4)  
     65-74 1,161,289 (44.9) 1,425,711 (55.1)  
     ≥ 75    894,707 (39.1) 1,390,646 (60.9)  
Sex 0.4899 
     Men 2,430,618 (54.8) 2,002,535 (45.2)  
     Women 3,174,081 (56.2) 2,468,825 (43.8)  
Race 0.0143 
     White 4,552,749 (55.3) 3,685,943 (44.7)  
     African American    399,601 (50.4)    393,249 (49.6)  
     Hispanic    402,539 (63.5)    231,205 (36.5)  
     Other    249,810 (60.8)    160,962 (39.2)  
Region 0.007 
     Northeast 1,192,725 (57.9)    866,216 (42.1)  
     Midwest 1,161,836 (52.6) 1,047,874 (47.4)  
     South 1,876,790 (52.1) 1,723,153 (47.9)  
     West 1,373,348 (62.2)    834,117 (37.8)  
Type of Cancerb 0.0415 
     Breast    905,173 (52.3)    825,795 (47.7)  
     Prostate/other male genital    700,133 (50.6)    682,770 (49.4)  
     Cervical/other female genital    367,847 (61.9)    226,886 (38.1)  
     Colon/other gastrointestinal    331,340 (51.4)    313,581 (48.6)  
     Melanoma    445,029 (60.9)    285,999 (39.1)  
     Leukemias and Lymphomas    233,040 (49.9)    234,362 (50.1)  
     Other/unspecified 2,622,137 (58.0) 1,901,966 (42.0)  
Healthcare Encounters <.0001 
     ≤ 4 1,763,347 (81.9)    389,527 (18.1)  
     5 - 9 1,671,371 (64.3)    927,650 (35.7)  
     10 - 19 1,352,039 (47.8) 1,475,045 (52.2)  
     ≥ 20     817,943 (32.8) 1,679,137 (67.2)  
Marital Status 0.0062 
     Married 3,554,793 (57.9) 2,584,969 (42.1)  
     Not Married 2,049,907 (52.1) 1,886,390 (47.9)  
Education Level <.0001 
     Less than High School 2,524,157 (52.7) 2,261,309 (47.3)  
     High School    909,690 (50.2)    901,685 (49.8)  
     Some College 2,170,853 (62.4) 1,308,365 (37.6)  
Income Levelc <.0001 
     Low  1,327,712 (46.5) 1,525,131 (53.5)  
     Medium 1,472,878 (55.1) 1,201,854 (44.9)  
     High 2,804,110 (61.7) 1,744,374 (38.3)  
Insurance Coverage <.0001 
     Private 4,175,600 (59.5) 2,840,116 (40.5)  
     Uninsured    316,594 (84.9)      56,407 (15.1)  
     Public 1,112,506 (41.4) 1,574,836 (58.6)  
Time since cancer diagnosis (years) 0.0005 
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      ≤ 2  1,013,155 (58.2)    727,923 (41.8)  
      3 - 5 1,023,246 (57.1)    767,357 (42.9)  
      6 - 10 1,826,313 (58.3) 1,305,332 (41.7)  
      > 10 1,741,987 (51.0) 1,670,750 (49.0)  
Arthritisd <.0001 
     Yes 1,806,317 (40.3) 2,670,963 (59.7)  
COPDd <.0001 
     Yes    537,824 (30.3) 1,235,408 (69.7)  
Diabetesd <.0001 
     Yes    442,667 (22.4) 1,531,746 (77.6)  
Heart conditionsd <.0001 
     Yes 2,112,035 (36.2) 3,717,153 (63.8)  
Anxiety disordersd <.0001 
     Yes    517,393 (33.7) 1,019,466 (66.3)  
Mood (depression + bipolar)d <.0001 
     Yes    555,323 (32.7) 1,140,712 (67.3)  
Notes:  aThe Medical Expenditures Panel Survey sets an upper limit of 85 years old.  
bType of cancer included the following categorizations: prostate (included testicular cancer and 
cancer of other male genitals), cervical (included uterine, ovarian, other female cancers), colorectal 
(esophageal, stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas, and other 
gastrointestinal cancers).  
cIncome level: low (<200% above poverty line), medium (200% to 400% above poverty line), high 
(>400% above the poverty line).  
dArthritis, chronic obstructive pulmonary disease (COPD), diabetes, heart conditions, anxiety and 
mood disorders are binary values (No=not present, Yes=present) listed in Appendix B.   
eChi-square statistics were used to assess significant differences. 
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Table 3. The 10 Most Frequently Prescribed Therapeutic Classes by Polypharmacy in US Adult 
(≥ 18 years) Cancer Survivors for 2008, 2010, 2012, 2014 (N=10,076,059), weighted n %. 
No Polypharmacy Polypharmacy 
Therapeutic Class n % Therapeutic Class n % 
Analgesics  5,641,955 9.8 Antihyperlipidemic 
Agents 
10,756,303 7.0 
Antihyperlipidemic 
Agents  
5,271,895 9.1 Analgesics 10,026,041 6.5 
Thyroid Hormones 2,594,923 4.5 Beta-Adrenergic 
Blocking Agents 
6,880,568 4.5 
Antidepressants 2,568,521 4.4 ACEIs 6,191,953 4.0 
Beta-Adrenergic 
Blocking Agents  
2,162,874 3.7 Antidepressants 6,059,182 3.9 
ACEIs  2,011,395 3.5 Proton Pump Inhibitors 6,008,914 3.9 
Dermatologic Agents 2,002,805 3.5 Diuretics 5,734,144 3.7 
Proton Pump Inhibitors 1,961,436 3.4 Antidiabetic Agents 5,501,999 3.6 
Macrolide Derivatives  1,875,861 3.2 Anticonvulsants 4,701,619 3.0 
Antihypertensive 
Combinations 
1,811,742 3.1 Thyroid Hormones  4,348,843 2.8 
Notes: ACEIs = Angiotensin Converting Enzyme Inhibitors.  
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Figure 2. Adjusted Mental and Physical Component Scores by Cancer Type, with or without 
Polypharmacy, Means with 95% Confidence Interval Bars (N =10,076,059). 
 
* = statistically significant mean differences between mean scores at alpha = 0.05. NoPP = No 
polypharmacy. PP = polypharmacy.  
Type of cancer included the following categorizations: prostate (included testicular cancer and cancer  
of other male genitals), cervical (included uterine, ovarian, other female cancers), colorectal 
(esophageal, stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas, and other 
gastrointestinal cancers).   
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Table 4. Unadjusted and Adjusted Regression Estimates (Beta) with Standard Errors (SE) of 
Significant Explanatory Variables Based on an Ordinary Least Squares Regression Model for 
Patient and Clinical Factors Associated with Physical Component Scores (PCS) in US Adult 
Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014 (N=10,076,059). 
 
Explanatory Variables Unadjusted Model Adjusted Model 
Beta (SE) P value Beta (SE) P value 
Polypharmacy 
     Yes -10.23 (0.51) <.0001 -3.75 (0.57) <.0001 
Age Group, years 
     18-49  Reference 
     50-64 -3.83 (0.69) <.0001 -1.29 (0.58) 0.0277 
     65-74 -6.19 (0.72) <.0001 -0.92 (0.65) 0.1600 
     ≥ 75 -9.99 (0.69) <.0001 -3.35 (0.71) <.0001 
Region 
     Northeast  Reference 
     Midwest -2.22 (0.83) 0.0085 -1.28 (0.76) 0.0951 
     South -2.69 (0.71) 0.0002 -1.84 (0.65) 0.0050 
     West 0.23 (0.77) 0.7610 0.24 (0.67) 0.7216 
Education Level 
     Less than High School -4.28 (0.53) <.0001 -1.16 (0.44) 0.0097 
     High School -5.84 (0.78) <.0001 -2.98 (0.64) <.0001 
     Some College  Reference 
Income Levela 
     Low -7.80 (0.64) <.0001 -3.65 (0.63) <.0001 
     Medium -3.51 (0.61) <.0001 -1.58 (0.53) 0.0034 
     High  Reference 
Insurance Coverage 
     Private  Reference 
     Public -7.16 (0.60) <.0001 -2.56 (0.56) <.0001 
     Uninsured -0.82 (1.30) 0.5289 -2.27 (1.16) 0.0518 
Arthritisb 
     Yes -8.72 (0.47) <.0001 -4.76 (0.50) <.0001 
 COPDb 
     Yes -8.62 (0.73) <.0001 -4.36 (0.67) <.0001 
Heart Conditionsb 
     Yes -8.01 (0.52)  <.0001 -2.83 (0.62) <.0001 
Diabetesb 
     Yes -7.50 (0.66) <.0001 -2.05 (0.53) <.0001 
Healthcare Encounters (no. of visits) 
     0 - 4  Reference 
     5 - 9 -1.32 (0.63) 0.0381 0.57 (0.51) 0.2716 
     10 - 19 -5.17 (0.71) <.0001 -0.69 (0.57) 0.2299 
     ≥ 20 -8.80 (0.76) <.0001 -3.71 (0.62) <.0001 
Notes: aIncome level: low (<200% above poverty line), medium (200% to 400% above poverty line), 
high (>400% above the poverty line).  
bChronic physical condition is a binary value (No=not present, Yes=present) for the conditions listed 
in Appendix B.   
The model fit was measured by its adjusted R2 value (0.35). 
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Table 5. Unadjusted and Adjusted Regression Estimates (Beta) with Standard Errors (SE) of 
Significant Explanatory Variables Based on an Ordinary Least Squares Regression Model for 
Patient and Clinical Factors Associated with Mental Component Scores (MCS) in US Adult 
Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014 (N=10,076,059). 
 
Explanatory Variables Unadjusted Model Adjusted Model 
Beta (SE) P value Beta (SE) P value 
Polypharmacy 
     Yes -2.84 (0.43) <.0001 -0.51 (0.51) 0.3145 
Age Group (years) 
     18-49  Reference 
     50-64 1.21 (0.61) 0.0467 1.35 (0.58) 0.0196 
     65-74 3.40 (0.66) <.0001 3.93 (0.69) <.0001 
     ≥ 75 3.05 (0.59) <.0001 3.86 (0.71) <.0001 
Time Since Cancer Diagnosis (years) 
     0-2 -1.78 (0.58) 0.0025 -1.64 (0.66) 0.0133 
     3-5 Reference  
     6-10 -0.36 (0.46) 0.4358 -0.34 (0.61) 0.5691 
     ≥ 11 -1.21 (0.51) 0.0178 -1.01 (0.71) 0.1514 
Income Levela 
     Low -5.49 (0.52) <.0001 -3.25 (0.53) <.0001 
     Medium -2.50 (0.54) <.0001 -1.47 (0.49) 0.0029 
     High  Reference 
Insurance Coverage 
     Private  Reference 
     Public -2.90 (0.49) <.0001 -1.27 (0.50) 0.0108 
     Uninsured -4.57 (1.20) 0.0002 -1.29 (1.12) 0.2473 
Type of Cancerb 
     Breast 1.08 (1.20) 0.3696 1.10 (1.15) 0.3354 
     Cervical/other female genital -1.50 (1.31) 0.2546 0.85 (1.24) 0.4907 
     Colon/other gastrointestinal -2.66 (1.29) 0.0413 -2.34 (1.13) 0.0381 
     Melanoma 1.84 (1.43) 0.2009 0.53 (1.21) 0.6619 
     Other/unspecified 0.08 (1.09) 0.9401 0.28 (1.02) 0.7843 
     Prostate/other male genital 2.42 (1.18) 0.0405 0.74 (1.15) 0.5224 
     Leukemias and Lymphomas  Reference 
Arthritisc 
     Yes -3.11 (0.46) <.0001 -1.78 (0.41) <.0001 
Anxiety Disordersd 
     Yes -5.88 (0.73) <.0001 -2.98 (0.67) <.0001 
Mood Disordersd 
     Yes  -10.1 (0.68) <.0001 -8.08 (0.67) <.0001 
Notes: aIncome level: low (<200% above poverty line), medium (200% to 400% above poverty line), 
high (>400% above the poverty line).  
bType of cancer included the following categorizations: prostate (included testicular cancer and 
cancer of other male genitals), cervical (included uterine, ovarian, other female cancers), colorectal 
(esophageal, stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas, and other 
gastrointestinal cancers).  
cArthritis is a binary value (Yes=present) and is listed in Appendix B.  
dAnxiety and mood disorders are listed in Appendix B.  
The model fit was measured by its adjusted R2 value (0.22). 
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2.1 Abstract 
 
PURPOSE: Prescription medications play a vital role in the lives of cancer survivors. 
However, they also contribute to rising healthcare expenditures in the United States 
(US). The objective of this study was to determine if polypharmacy (PP) is associated 
with increased healthcare expenditures among cancer survivors in the US. 
METHODS: A cross-sectional study analysis of data from the Medical Expenditure 
Panel Survey (MEPS), a set of surveys of non-institutionalized individuals, 
households, their medical providers and employers throughout the US was conducted. 
The analytic sample included all patients 18+ years of age who had a diagnosis code 
for a single type of cancer, excluding nonmelanoma skin cancers, during even years 
2008-2014. PP was defined as the reported use of ≥ 5 distinct therapeutic classes of 
prescribed medication during the panel (year). Healthcare expenditures were measured 
as the total direct payments per annum from all reported sources in 2017 dollars. We 
used ordinary least squares regression with log transformed expenditures as our 
dependent variable adjusting for various demographic and clinical variables. 
RESULTS: PP was present in 43.9% (10.6 million, weighted per year) of cancer 
survivors included in this study. The per annum total direct medical expenditures for 
all cancer survivors in the US was $162.6 billion. The mean annual adjusted 
healthcare expenditures per cancer survivor with PP was $13,266 (SD $3,766), which 
was significantly higher than those without PP $8,753 (SD $5,082, p-value <.0001). 
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CONCLUSION: Cancer survivors with polypharmacy accounted for 70% of total 
annual medical expenditures among cancer survivors. PP was associated with higher 
expenditures across cancer types, intensity of utilization, and setting of care. 
IMPLICATIONS FOR CANCER SURVIVORS: Cancer survivors should be aware 
that increased prescription medication use is associated with increased total healthcare 
expenditures. 
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2.2 Introduction 
 
National health expenditures in the United States (US) increased by 3.9% from 
2016 to 2017, and made up 17.9% of gross domestic product, totaling $3.5 trillion 
dollars according to the Centers for Medicare and Medicaid Services (CMS).1 On 
average, this amounted to $10,739 per person in the US.1 The estimated 2017 national 
expenditures on cancer care was $147.3 billion and is expected to increase to $157.8 
billion in the Medicare population alone by 2020.2   
 
Cancer was the sixth most expensive condition to treat in the US in 2015.3 
Most cancers are estimated to have a decreasing incidence and increasing survival rate 
for the foreseeable future.2 A decreasing incidence may cause overall cancer-related 
expenditures to decline in the long run, but the prevalence of cancer coupled with the 
aging of the US population will result in an increase in the number of cancer 
survivors. Thus, increases in expenditures during treatment through end of life, the 
period of time which defines a cancer survivor,4 are expected to continue to increase in 
coming years,2 given that cancer survivors are estimated to increase from 15.5 million 
in 2016,4 to 26.1 million by 2040.5   
 
Cancer survivors face several major challenges including financial hardship, 
body image/self-esteem issues, and anxiety surrounding fears of long-term side-effects 
of treatment and cancer recurrence.6 As part of some cancer survivors’ treatment plans 
(e.g. breast cancer), they may take medications (adjuvant hormonal therapy) for the 
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following 5 to 10 years to lower the risk of recurrence.7 Adjuvant therapy, for 
example, may increase the quantity of medications the survivor is to define them as 
having polypharmacy (PP), most commonly defined as the use of ≥ 5 concomitant 
medications.8 Because survivors may have already been taking numerous medications 
to treat comorbid conditions and for palliative care one additional medication may 
now qualify as reaching the PP threshold.9 PP is known to be highly prevalent and is 
associated with higher prescription costs among cancer survivors.10  
 
The types of services and healthcare products cancer survivors require 
included in the national health expenditure estimates are hospital care, physician and 
clinical services, other professional services (specialists), dental services, home health 
care, nursing care facilities, medical equipment, prescription drugs, and various other 
services and products.1 Hospital-based care comprised 33% of health spending (the 
largest percentage), whereas physician and clinical services made up 20%, and other 
health and personal care services totaled 5%, with the other groups (excluding 
prescription drugs) comprising the remainder.1 Prescription drugs dispensed through 
retail pharmacies accounted for roughly 10% of the $3.5 trillion dollars spent on the 
total population for healthcare in 2017;1 and expenditures on cancer treatments are 
expected to increase over time as new drugs tend to be more expensive than current 
standards of care.11   
 
With prescription drugs comprising a significant portion of cancer-related 
expenditures, this study was conducted to examine the association between the 
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number of medications prescribed and healthcare expenditures among cancer 
survivors. The objective of this study was to expand current knowledge by examining 
the relationship between polypharmacy and direct healthcare expenditures. 
Quantifying the relationship between polypharmacy and healthcare expenditure in 
cancer is a requisite first step to understand the need for further study in determining 
to what degree increased healthcare expenditure is attributable to medication-related 
adverse events, or if polypharmacy is merely a proxy for burden of illness. 
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2.3 Methods 
 
Study design and data source 
We used a multi-year cross-sectional study design and utilized the Medical 
Expenditures Panel Survey (MEPS) database, a publicly available de-identified 
nationally representative database of the US.12 The MEPS is a set of surveys 
containing nationally representative non-institutionalized persons, households 
(families and individuals), their medical providers, and employers throughout the US 
since 1996.12 The MEPS uses a 2-year, 5-panel overlapping survey design of 
interviews. 
 
We first used the medical conditions file to find individuals who reported 
cancer by using the cancer specific diagnosis codes through the Agency for Healthcare 
Research and Quality (AHRQ) clinical classification code system (Appendix A). We 
then linked the medical conditions, prescribed drugs, and household data files through 
a unique identifier for each individual cancer survivor.12 We also used these clinical 
classification codes and the ICD-9-CM codes to identify concurrent chronic conditions 
using AHRQ’s Elixhauser comorbidity codes.13 Further details regarding the MEPS 
have been described elsewhere.12  
 
Sample selection 
The analytic sample included cancer survivors who were defined as adults (≥ 
18 years old) with cancer who (1) responded ‘Yes’ to the MEPS survey question: 
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“Have you ever been told by a doctor or other health professional that you had cancer 
or a malignancy of any kind?”; and (2) were alive at the end of the reference panel 
year. For our analyses we pooled data from years 2008, 2010, 2012, and 2014. In the 
MEPS, individuals are followed for two years, so to avoid including repeated 
observations we selected even years only. We excluded people with zero person-level 
sample weights and survivors with nonmelanoma skin cancer because treatment for 
basal and squamous cell carcinomas are often non-invasive compared to melanoma. 
Individuals also were excluded if they had more than one type of cancer due to the 
inability to determine an association between the person’s total expenditures and one 
cancer type. Men with breast cancer were excluded because of small sample size and 
lack of generalizability to female breast cancer survivors. People under the age of 18, 
with missing age information, had an age at diagnosis greater than their reported age, 
or who died during the panel year were excluded. Figure 1 shows a flowchart of 
inclusion and exclusion criteria. 
 
Measures  
Dependent variable: Direct healthcare expenditures 
Mean annual direct healthcare expenditures incurred per US cancer survivor 
was the dependent variable of interest. The expenditures represent the total direct 
payments from all reported sources to hospitals (facility and separately billed 
physicians), physicians, other medical, home health providers, for other providers, for 
dental providers, for miscellaneous expenses, and for prescriptions (Appendix C).14 
We created 5 distinct categories for expenditures: hospital, office-based, emergency 
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room, prescriptions, and other medical expenses. Hospital expenditures were the 
summation of the expenditures from the hospital outpatient visits and inpatient stays. 
Other medical expenditures included dental visits, home health providers (agency 
sponsored and paid independent provider), vision, and other medical expenses. Office-
based, emergency room, and prescription expenditures were standalone categories 
within the MEPS. These expenditure groupings, when summed, equaled that of the 
total direct annual healthcare expenditures per cancer survivor. 
 
Key independent variable 
Polypharmacy (PP) 
The MEPS include a prescriptions file with therapeutic medication class 
information which are linked to the Multum Lexicon database for analysis.15 We used 
these therapeutic class details to determine the maximum number of distinct classes of 
prescription medications the individuals were on in one of the panels that coincided 
with our study years. A consensus definition of PP does not currently exist; however, 
the most common definition in the literature is 5 or more concomitant medications.8 
We chose 5 or more classes of medications as our definition for PP based on our 
review of the literature which included several studies which used classification 
classes.16,17 
  
Other independent variables 
Demographic variables included age group, sex, race/ethnicity, US geographic 
region (Northeast, South, Midwest, and West), and marital status (married or not 
48 
 
married). Socioeconomic variables included income (low, middle, high based on 
poverty level), insurance status (privately-, publicly-, or uninsured), and level of 
education (did not graduate high school, graduated but did not attend college, and at 
least some college level education). Time since cancer diagnosis was calculated by 
subtracting age at diagnosis, a variable included in the MEPS, from the patient’s 
reported age. For patients who could not remember their age at diagnosis or was 
otherwise missing from the dataset, 51.7% total missingness, multiple imputation was 
used to fill in these missing values. We used the fully conditional specification (FCS) 
method, with all variables in the model creating 40 imputed data sets.18 These data sets 
were then combined to get mean estimates across all variables. 
 
Clinical variables included type of cancer, Elixhauser comorbidity score, and 
number of total provider encounters. Cancer type was grouped in the following 
manner: breast, prostate and other male genital (included testicular cancer), cervical 
and other female genital (included uterine, ovarian, other female cancers), colon and 
other gastrointestinal (GI) (stomach, liver, pancreas, and other GI cancers), melanoma, 
leukemias/lymphomas and other/unspecified (included lung). Lung cancer was 
grouped into the “other/unspecified” group due to small sample size. We used the 
Elixhauser comorbidity score to assess physical and mental diseases and disorders due 
to its well-established validity. The Elixhauser comorbidity score is the summation of 
approximately 31 comorbid conditions, which are first dichotomized as being present 
or absent in the patient, which we then categorized based on its distribution using 
quartiles to 0, 1, 2 or ≥ 3 (Appendix D).13 Survivors with both complicated and 
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uncomplicated diabetes or hypertension diagnoses were assumed to have the 
complicated, more severe, state of disease for these analyses. Provider encounters 
were defined as total provider or outpatient visits obtained from the household files 
and categorized into 0-4, 5-9, 10-19, and ≥ 20 visits based on quartiles.  
 
Statistical analysis 
Significant differences in per-person mean annual direct expenditures between 
cancer survivors with and without PP were assessed using t-tests and analysis of 
variance (ANOVA), stratifying by type of cancer. Due to the positively skewed nature 
of the expenditures, a natural logarithm transformation was used to normalize the 
dependent variable. To fit a valid model for the log transformed expenditures we 
excluded patients with zero expenditures (n=28). A subgroup-specific smearing factor 
was applied after retransformation (exponentiation of beta estimate) to approximate 
nominal dollar values because without the smearing factor the estimates would be 
biased toward $0.19 Expenditures were adjusted for inflation to 2017 US dollars using 
the Bureau of Labor Statistics consumer price index for medical care services.20 
 
The primary analysis was to estimate the association between PP and total 
healthcare expenditures. Potential covariates were assessed in univariate OLS models 
for their statistical significance. If a variable was significantly associated with both PP 
and healthcare expenditures (F test p-value <0.10) it was included for assessment in a 
multivariable ordinary least squares (OLS) model. Multivariable (OLS) regression 
models were used to assess the relationship between PP and healthcare expenditures 
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while controlling for significant covariates. An iterative process was used to include 
individual covariates one at a time into the multivariable OLS model based on its F 
test p-value. If a covariate was insignificant after placement into the model it was 
removed, and the model was run again with the next covariate, until no more 
significant covariates remained for analysis.  
 
In a secondary analysis, the relationships between PP and healthcare 
expenditures were modeled by setting of care overall, and by setting of care and type 
of cancer. Separate models were created for each of the log expenditures from the 5 
settings of care as the dependent variables, controlling for all significant covariates 
from the primary analysis. OLS regression was used to analyze mean expenditures by 
PP for each setting overall. To estimate the mean expenditures for a woman with 
breast cancer, we first created a cohort of women with breast cancer, then we 
separately modeled the per-patient mean expenditures with each setting as a dependent 
variable. OLS regressions were used to find mean differences in expenditures by PP in 
both secondary analyses.  
 
Due to the complexity of the survey design used in the MEPS; stratification, 
clustering, and weighting were performed. Significance tests were all performed at the 
α = 0.05 level. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, 
NC). 
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2.4 Results 
 
The study population consisted of 3,435 (N= 10,580,285 weighted) adult 
cancer survivors (Figure 1, Table 1). The three most prevalent types of cancer were 
female breast (17.2%), prostate (14.0%, and melanoma (7.0%) (Table 1). Of these, 
1,523 (N= 4,649,586 weighted, 43.9%) adults reported use of 5 or more therapeutic 
classes of prescribed medications. Older survivors (≥75 years) were most likely 
(60.8%) to have PP; while the youngest survivors (18-49 years) were least likely to 
have PP (18.4%). Most cancer survivors (54.0%) had at least 2 comorbid conditions, 
with over one-third (34.2%) having at least 3. Weighted percentages for all other 
demographic, socioeconomic, and clinical variables categorized as with or without 
polypharmacy are included in Table 2. 
 
PP and prescription medication utilization 
 There were approximately 55 million (weighted) prescribed medications per 
year for the total cohort of cancer survivors: 72.5% (40.1 million (M)) of these 
prescriptions were to respondents defined as having PP (not shown). Those without PP 
were on 90 distinct therapeutic classes compared to 93 for those with PP. Of those 
therapeutic classes, 92.6% (88/95) were not unique between those without PP and 
those with PP. Antihyperlipidemic medications comprised the most commonly 
prescribed chronically used therapeutic class for both those with (7.0%; 2.8M 
weighted prescriptions) or without (9.2%; 1.4M) PP. Beta-adrenergic blocking agents 
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were the second most prevalent therapeutic class in those with PP (4.5%; 1.8M) (Table 
3). 
 
Overall expenditure differences by PP 
The unadjusted and untransformed mean per-patient direct healthcare 
expenditures for the overall study cohort was $15,369 (95% CI: $14,146-$16,591). 
The total per year expenditures averaged $162.6 billion, adjusted to 2017 dollars. 
Those with PP accounted for 70.3% of the total annual mean expenditures. The total 
annual mean expenditures were $21,652 (95% CI: $18,485-$24,820) for those with PP 
and $13,414 (95% CI: $9,952-$16,875) for those without PP, resulting in a 
significantly different (p-value <.0001) mean difference of $8,239 (Table 4). 
 
Total mean annual expenditures by setting of care and PP 
Mean annual adjusted expenditure in the hospital setting was the largest 
contributor to total annual expenditures for cancer survivors (Figure 2). Expenditures 
for cancer survivors in the hospital setting amounted to $68.8 billion (B) (standard 
deviation: SD $22.9B) annually and comprised 42.3% of total spend by setting. 
Hospital-based expenditures accounted for 42.0% ($21.9B SD $9.7B) of $52.1B (SD 
$13.8B) total annual expenditures for cancer survivors without PP. For those with PP, 
hospital-based expenditures comprised 42.5% ($47.0B SD $21.3B) of $110.5B (SD 
$28.2B) total expenditures per year. Prescription medicines for all cancer survivors 
made up 19.9% ($32.3B SD $6.7B) of total annual expenditures. For survivors with 
PP, prescriptions made up 76.5% ($24.7B SD $5.1B) of total annual expenditures 
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compared to 23.5% ($7.6B) for those without PP. Other medical expenditures totaled 
8.6% ($14.0B SD $7.4B) of total annual expenditures by setting. Survivors with PP 
accounted for 71.4% ($10.0B SD $7.4B) of other medical expenditures. Emergency 
room expenditure accounted for 2.3% ($3.7B SD $2.1B) and was the smallest 
contributor to total annual mean expenditures in both those with polypharmacy and 
those without PP (2.3% ($2.6B SD $1.9B) and 2.2% ($1.1B SD $527M), 
respectively). 
 
Expenditure differences by setting of care and PP 
Table 4 shows the smear-adjusted log transformed mean expenditures for each 
setting of care by PP. Mean expenditures were higher for each setting, except for 
office-based visits, with the highest average mean expenditures being spent in the 
hospital setting for those with PP ($12,314 95% CI: $9,981-$15,040). However, 
differences in mean expenditures by PP for both office-based ($2,350 CI: 2,126-
$2,571 vs. $2,410 CI: $2,203-$2,637 p-value 0.3146) and emergency room ($2,444 
CI: $2,021-2,927 vs. $1,598 CI: $1,308-$1,952 p-value 0.0921) settings were not 
significantly different than for those without PP.  
 
Expenditure differences by type of cancer, setting of care, and PP 
 Figure 3 presents the results from smear-adjusted OLS analyses of mean 
transformed expenditures by settings of care and type of cancer by PP status, which 
controlled for significant variables. Across all types of cancer, except for melanoma 
($7,709 vs. $16,922, p-value 0.4739), expenditures in the hospital setting for survivors 
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with PP were higher than for those without PP. However, only leukemias & 
lymphomas and other/unspecified cancer types were significantly higher in those with 
PP than without PP ($19,114 vs. $8,742 p-value 0.0048 and $12,964 vs.8,943 p-value 
0.0073, respectively). For office-based care, mean expenditure differences were 
significantly higher in those with PP for only the other/unspecified cancer type 
($2,296 vs. $2,069 p-value 0.0206). Emergency room mean differences for 
expenditures were significantly higher in survivors with PP and leukemias and 
lymphomas ($2,437 vs. $641, p-value 0.0067), melanoma ($765 vs. $403, p-value 
<.0001), and the other/unspecified cancer categories ($3,330 vs. $1,689, p-value 
0.0471). Mean expenditures differences between the other medical category were 
significantly different for breast cancer ($2,242 vs. $1,036 p-value 0.0088) and 
colorectal ($4,955 vs. 1,505 p-value .0243). For each type of cancer, the modeled 
values for prescription medication expenditures were significantly higher (p-value 
<0.0001) in all survivors with PP compared to those without PP.  
 
Associations between PP and healthcare expenditures 
As seen in Table 5, PP was significantly associated with higher total annual 
mean log expenditures (β= 0.60, SE=0.05, p-value <.0001) when controlling for all 
significant variables (age, insurance, cancer type, comorbidity, provider encounters, 
and time since cancer diagnosis). This estimate represents an 82% increase in the total 
annual mean log expenditures due to a one-unit increase of the average number of 
cancer survivors having PP, holding all other variables at their reference class. 
 
55 
 
Several covariates had significant differences from their referent group in their 
association with total annual mean expenditures. All types of cancer examined, except 
for cervical and other female genital cancers, were significantly different from 
melanoma in their association with log expenditures while controlling for PP, age, 
insurance, time since cancer diagnosis, comorbidity, and provider encounters (Table 
5). Colon and other GI cancers was the most significantly different (β= 0.57, SE 0.11, 
p-value <.0001) from melanoma (reference group) with a 76% increase in mean log 
expenditures. Survivors with ≥ 3 comorbid conditions had a significant 37% increase 
from those without any comorbidities (β= 0.31, SE 0.06, p-value= <.0001). Survivors 
with public insurance (β= -0.12, SE 0.04, p-value= 0.0023) and without any insurance 
(β= -0.42, SE 0.14, p-value= 0.0029) were associated with lower mean log 
expenditures than survivors with private insurance (12% and 34%, respectively). 
Those aged 50-64 were significantly different from their referent group of 18-49 years 
(β= 0.19, SE 0.06, p-value= 0.0014) with an associated 20% increase in mean log 
expenditures. Lastly, the number of visits to a provider was progressively significant 
and by far the most associated with increased mean log expenditures, with ≥ 20 
encounters having a 540% increase in mean log expenditures (β= 1.85, SE 0.08, p-
value <.0001) (Table 5). Time since cancer diagnosis of 2 years or less was 
significantly different in mean log expenditures compared to cancer survivors of 3 to 5 
years by an increase of 36% (β= 0.31, SE 0.08, p-value <.0001). 
 
After applying the subgroup-specific smear factors to the retransformed 
(exponentiated) estimates of the adjusted mean expenditures, the annual expenditure 
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for someone with PP was $13,226 (SD $3,766), which was $4,513 more than 
survivors without PP at $8,753 (SD $5,082), and was significant (p-value <.0001). 
The log expenditure estimates, subgroup-specific smearing factors, and final adjusted 
values are presented in Table 6. 
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2.5 Discussion 
 
In this study, we found that approximately 44 of 100 adult cancer survivors per 
year were defined as having PP. PP was associated with significantly higher mean 
annual direct healthcare expenditures in all analyses, including unadjusted, adjusted, 
and our log transformed multivariable OLS model. Unadjusted total mean 
expenditures for cancer survivors in our study were higher than the 2012 estimated 
expenditures reported by AHRQ for the general population by 89% ($15,369 vs. 
$8,125, respectively).21 For survivors with PP, the unadjusted difference in mean 
expenditures was associated with an increase of 70% in spending, with annual spend 
equaling $21,652 compared to $13,414 for survivors without PP. In the adjusted 
analysis, PP was associated with a significant 82% increase in the estimated log 
expenditures compared to those without PP. 
 
By comparing the various settings of care for cancer survivors, we found that 
spending in the hospital setting is higher compared to the other settings, for both those 
with and without PP, which aligns with prior research.1 Hospitalization has been 
linked to increased medication use in older cancer patients.9,22  However, hospital-
based expenditures for those both with or without PP were approximately 42% of 
spend by setting, higher than that in the general population (33%).1 The largest 
differences for cancer survivors with versus without PP by setting were office-based 
(23.7% vs. 33.7%, respectively) and prescription medications (22.4% vs. 14.6%, 
respectively). These amounts were also higher as a proportion of spending by setting 
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compared to the general population (20% for office-based and 10% for prescription 
medication).1 We combined expenditures from both inpatient and outpatient hospital 
visits while other studies have categorized hospital costs based solely on inpatient 
hospitalizations versus ambulatory (outpatient) hospital visits and office-based visits.23 
This may be why hospital-based expenditures were so much higher than office-based 
visits in this study. Our analysis provides further evidence that cancer survivors have 
substantially greater direct healthcare expenditures than the general population.  
 
Differences existed among the different types of cancers, regarding overall 
healthcare expenditures for those with PP compared to those without PP. In the 
adjusted analyses, where we controlled for all significant variables, total annual mean 
expenditures for those with colon or other GI cancers were the highest, although not 
statistically significant from other cancer types. In a 2016 study of the economic 
burden (defined as annual medical expenditures plus annual productivity losses) of 
colorectal, female breast, and prostate cancer survivors in the US, which also used the 
MEPS (years 2008-2012), colorectal cancer was associated with the highest annual 
expenditures and productivity losses of the three cancer types.23   
 
Various risk factors for PP among cancer patients include comorbid conditions, 
hospitalization, and unnecessary prescribing.9 Most cancer survivors in the current 
study had at least 2 comorbid conditions. When examined closer by PP, 6% of those 
without a chronic condition were defined as having PP; while 78.2% of those with ≥ 3 
conditions had PP. In the log transformed expenditure model, having ≥3 comorbid 
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conditions was associated with a 37% increase in expenditures compared to not having 
any comorbid conditions. Due to the cross-sectional study design, we cannot 
determine causality, but there was a clear association between PP and expenditures. 
Future research that focuses on the examination of individual comorbid conditions and 
the number of prescriptions an individual are on both pre- and post- cancer diagnosis 
would elucidate this relationship further, as it was not the emphasis of this research. 
 
We identified one paper that examined healthcare expenditure differences 
among cancer survivors with PP, in which they estimated median prescription 
expenditures as $1,633 vs. $784 in noncancer controls, but did not analyze total 
expenditure values.10 Knowing that prescription costs significantly differ among 
cancer survivors with PP, as well as noncancer counterparts with PP, is important for 
addressing disparities among cancer survivors with and without PP. One reason for the 
disparities is that spending on anticancer medications doubled from 2012-2017 to 
almost $50 billion, with all oncology drugs launched in 2017 having list prices above 
$100,000.24 In the US, the cancer drug market is expected to grow 12-15% annually 
by 2020, up to $100 billion.24 This growth is expected to be driven by new launches 
and increased uptake of existing branded oncologics.24 However, one positive trend is 
that oncology drug prices have risen at a slower rate (4.7%-6.4%) on average than that 
of the general branded market (6.9%) from 2012-2017.24 We chose to incorporate total 
healthcare expenditures by PP among cancer survivors to see differences at the person 
and societal levels. In so doing, we hope that policymakers could be informed about 
how influential PP is on the healthcare system in the US. 
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This study determined that the total annual expenditure estimates for US 
cancer survivors for the period of 2008-2014, adjusted to 2017 dollars was $162.6 
billion. According to research which used SEER-Medicare data, the estimated costs of 
cancer care will equal $157.8 billion by 2020.25 However, when taking into 
consideration the declining incidence for most cancers, improving survival rates, and 
increasing costs, the authors estimated the total cost could amount to $172.8 billion.25 
Our estimate concurs with this as it is in the upper range of these two estimates. 
 
Increased healthcare costs can have negative effects on both the individual 
cancer survivor and society as a whole.26 For cancer survivors, concerns over 
outcomes previously linked to PP include adverse drug events, drug-drug interactions, 
increased morbidity, decreased survival, frailty/disability, and poor medication 
adherence.9 On the societal level, policymakers may have to address the increased 
expenditures related to prevention initiatives and various adverse health-related 
outcomes in this expanding vulnerable population. PP may cause increased healthcare 
expenditures because of additional therapeutic monitoring, lab tests, physician office 
visits, and follow-up care planning. 
 
Currently in the US, the focus of various advocacy and governmental groups 
focuses on lowering the cost of prescription medications. Although this is certainly 
needed, for cancer survivors whom are mostly covered by private or public insurances, 
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a closer look at hospital and office-based expenditures should also be highly 
scrutinized due to the largest proportions of expenditures being spent in those areas. 
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2.6 Limitations 
 
As this was a cross-sectional study design, no claim of causality can be made. 
Other limitations may exist due to the way the data was collected, through 
computerized survey. Recall bias may have impacted the answers to the survey as 
some respondents may not have an accurate recollection of life events due to various 
reasons (e.g. older age, responding for another household member). The MEPS uses a 
3-digit coding system for ICD-9-CM codes, and thus the nuances of certain comorbid 
conditions may not be recorded. Likewise, using the Elixhauser comorbidity score 
dichotomizes conditions and does not consider differences in severity of comorbid 
conditions. No severity or stage of cancer for the survivors is recorded which would 
otherwise explain large differences in expenditures of survivors of the same type of 
cancer. For this analysis, based on sample sizes of individual cancers, we grouped 
various cancers together which may obfuscate more precise expenditure differences 
among those survivors.  
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2.7 Conclusion 
 
Mean total annual expenditures for cancer survivors with PP was significantly 
higher than for those without PP, with significant differences attributable to setting of 
care, intensity of utilization, and type of cancer. Understanding this association is the 
first step to addressing the underlying causes of expenditure differences among those 
cancer survivors with versus without PP. 
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Figure 1. Selection of Patients for Analyses of Prevalence of Polypharmacy in Adult Cancer 
Survivors (≥ 18 years) (2008, 2010, 2012, 2014), Unweighted. 
 
  
3,707 (65.5%) All valid cancer 
patients of interest  
3,435 (60.6%) Adult Cancer 
Survivors in Study Sample  
5,664 All patients who self-reported 
being diagnosed with cancer 2008, 
2010, 2012, 2014 
5,551 (98.0%) All cancer patients 
with a valid person weight 
272 (7.3%) Excluded patients who 
had $0 total expenditure value (28; 
0.7%), missing age (112; 3.0%), < 18 
years (70; 1.9%), died in round (61; 
1.6%), or age at diagnosis was > 
current age (1; <0.1%).  
113 (2.0%) Excluded patients with 
zero person-weight information. 
1,844 (33.2%) Excluded patients 
with nonmelanoma skin cancer 
(1,183; 21.3%) or more than one type 
of cancer diagnosis (659; 11.9%); 
men with breast cancer (2; <0.1%).  
1,912 (55.7%)  
No Polypharmacy 
 
1,523 (44.3%) 
Polypharmacy 
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Table 1. Distribution of Cancer Diagnoses in Adult Cancer Survivors (≥ 18 years) (2008, 2010, 
2012, 2014) of Interest Available in MEPS. 
Type of Cancer N (%), unweighted N, weighted 
Breast  613 (17.2%) 1,820,759 
Prostate and other male genital 484 (14.0%) 1,486,297 
Cervical and other female genital 228 (5.7%) 607,562 
Colon and other GI  250 (6.4%) 673,767 
Melanoma 193 (7.0%) 741,584 
Leukemias and lymphomas 160 (4.7%) 493,481 
Other / unspecified 1,507 (45.0%) 4,756,835 
Total 3,435 (100.0%) 10,580,285 
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Table 2. Demographic and Clinical Characteristics of Adult Cancer Survivors (≥ 18 years) with 
Cancer Diagnoses of Interest during 2008, 2010, 2012, 2014, by Polypharmacy Status (N= 
10,580,285). 
Demographic and Clinical 
Characteristics of Cancer 
Survivors 
No Polypharmacy Polypharmacy 
p-value 
(N= 5,930,699 | 56.1%) (N= 4,649,586 | 43.9%) 
Age group (years)a   <.0001 
     18-49  1,746,353 (81.6%)    393,978 (18.4%)  
     50-64 2,019,881 (60.3%) 1,327,615 (39.7%)  
     65-74 1,222,852 (45.5%) 1,467,364 (54.5%)  
     ≥ 75    941,613 (39.2%) 1,460,629 (60.8%)  
Sex   0.8300 
     Men 2,619,191 (55.8%) 2,073,216 (44.2%)  
     Women 3,311,508 (56.2%) 2,576,370 (43.8%)  
Race/ethnicity   0.0109 
     White 4,819,924 (55.8%) 3,824,725 (44.2%)  
     African American    415,971 (50.4%)    409,089 (49.6%)  
     Hispanic    429,810 (63.6%)    245,621 (36.4%)  
     Other    264,994 (60.9%)    170,151 (39.1%)  
Region   0.0158 
     Northeast 1,232,839 (57.7%)    904,430 (42.3%)  
     Midwest 1,224,135 (52.8%) 1,096,576 (47.2%)  
     South 2,002,800 (53.1%) 1,770,205 (46.9%)  
     West 1,470,925 (62.6%)    878,375 (37.4%)  
Provider Encounters    <.0001 
     ≤ 4 1,914,471 (81.6%)    432,042 (18.4%)  
     5 - 9 1,773,239 (64.9%)    957,942 (35.1%)  
     10 - 19 1,407,070 (48.0%) 1,524,128 (52.0%)  
     ≥ 20     835,919 (32.5%) 1,735,474 (67.5%)  
Marital Status   0.0168 
     Married 3,723,611 (58.0%) 2,694,351 (42.0%)   
     Not Married 2,207,088 (53.0%) 1,955,235 (47.0%)   
Education Level   <.0001 
     Less than High School 2,661,512 (52.9%) 2,374,522 (47.1%)  
     High School    943,463 (50.6%)    920,694 (49.4%)  
     Some College 2,325,724 (63.2%) 1,354,370 (36.8%)  
Income Levelb   <.0001 
     Low 1,378,526 (46.4%) 1,593,485 (53.6%)  
     Medium 1,555,858 (55.4%) 1,250,218 (44.6%)  
     High 2,996,315 (62.4%) 1,805,883 (37.6%)  
Insurance Coverage   <.0001 
     Private 4,428,221 (59.9%) 2,958,484 (40.1%)  
     Public 1,179,479 (42.0%) 1,631,759 (58.0%)  
     Uninsured    322,999 (84.5%)    59,343 (15.5%)  
Type of Cancerc   0.0597 
     Breast    946,815 (52.0%)    873,945 (48.0%)  
     Prostate/other male genital    787,573 (53.0%)    698,724 (47.0%)  
     Cervical/other female genital    377,641 (62.2%)    229,921 (37.8%)  
     Colon/other gastrointestinal    338,687 (50.3%)    335,080 (49.7%)  
     Melanoma    448,397 (60.4%)    293,187 (39.6%)  
     Leukemias and lymphomas    255,124 (51.7%)    238,358 (48.3%)  
     Other/unspecified 2,776,462 (58.4%) 1,980,371 (41.6%)  
Time since cancer diagnosis 
(years)   0.0014 
     0-2          1,056,198 (58.2%)              759,676 (41.8%)  
     3-5          1,071,483 (58.1%)              773,356 (41.9%)  
     6-10          1,964,487 (58.3%)          1,404,582 (41.7%)  
     > 10          1,838,531 (51.8%)          1,711,972 (48.2%)  
70 
 
Elixhauser Comorbidityd   <.0001 
     0 2,209,455 (94.9%)  118,926 (5.1%)  
     1 1,921,954 (75.6%)    621,467 (24.4%)  
     2 1,010,014 (48.3%)  1,083,265 (51.7%)  
     ≥ 3 789,276 (21.8%) 2,825,929 (78.2%)  
Notes: aThe Medical Expenditures Panel Survey sets an upper limit of 85 years old.  
bIncome level: low (<200% above poverty line), medium (200% to 400% above poverty line), high (>400% 
above the poverty line).  
cType of cancer included the following categorizations: prostate (included testicular cancer and cancer of 
other male genitals), cervical (included uterine, ovarian, other female cancers), colorectal (esophageal, 
stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas, and other gastrointestinal cancers). 
dElixhauser Comorbidity Score: The summation of a binary variable (Present/Absent) for each of the 
comorbid conditions in the group of conditions (Appendix D).  
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Table 3. Top 10 Most Frequently Prescribed Therapeutic Classes among Patients with and 
without Polypharmacy, in US Adult Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014 
(N=10,580,285) weighted n, %. 
No Polypharmacy Polypharmacy 
Therapeutic Class Rx (n) Rx 
(%) 
Therapeutic Class Rx (n) Rx 
(%) 
Antihyperlipidemic 
Agents 
1,395,299 9.2% Antihyperlipidemic Agents 2,809,821 7.0% 
Thyroid Hormones 693,981 4.6% Beta-Adrenergic Blocking 
Agents 
1,794,952 4.5% 
Antidepressants 680,754 4.5% Antidepressants 1,607,836 4.0% 
Beta-Adrenergic 
Blocking Agents 
548,796 3.6% Angiotensin Converting 
Enzyme Inhibitors 
1,608,534 4.0% 
Angiotensin Converting 
Enzyme Inhibitors 
524,150 3.4% Proton Pump Inhibitors 1,558,512 3.9% 
Dermatological Agents 519,554 3.4% Diuretics 1,461,365 3.6% 
Proton Pump Inhibitors 503,199 3.3% Antidiabetic Agents 1,421,401 3.5% 
Antihypertensive 
Combinations 
459,858 3.0% Anticonvulsants 1,264,175 3.2% 
Antidiabetic Agents 415,267 2.7% Thyroid Hormones 1,132,490 2.8% 
Diuretics 408,366 2.7% Bronchodilators 914,132 2.3% 
Notes: Rx(n) = Total weighted number of prescribed therapeutic classes to cancer survivors on 
average for the years 2008, 2010, 2012, 2014. Rx(%) = Average annual number of prescribed 
therapeutic classes as a weighted percentage of total average annual by polypharmacy. 
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Figure 2. Expenditures Among US Adult Cancer Survivors (≥ 18 years) by Setting of Care and 
Polypharmacy for 2008, 2010, 2012, 2014, (%). 
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Table 4. Adjusted Mean Annual Total Expenditures by Setting of Care and Polypharmacy, in US 
Adult Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014 (N=10,580,285), Weighted ($US) 
Settings of Care Mean (95% CI), $US  
p-value 
Mean 
Difference 
($) No Polypharmacy Polypharmacy 
Hospital 9,398 (7,542 - 11,829) 12,314 (9,981 - 15,040) 0.0018 2,915 
Prescriptions 1,709 (1,531 - 1,908) 4,056 (3,707 - 4,483) <.0001 2,347 
Office-based 2,410 (2,203 - 2,637) 2,350 (2,126 - 2,571) 0.3146 (60) 
Other medical 1,127 (1,030 - 1,233) 2,447 (2,192 - 2,759) <.0001 1,320 
Emergency room 1,598 (1,308 - 1,952) 2,444 (2,021 - 2,927) 0.0921 846 
Notes: Values are adjusted variables significantly associated with log expenditures and may include a 
combination of any of the following variables: age group, gender, race, region, number of provider encounters, 
marital status, comorbidity score, education level, poverty level, and insurance coverage. 
*Values are rounded to nearest whole dollar value or percent where applicable.  
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Figure 3. Results of Ordinary Least Squares Regression Describing Adjusted Mean Log 
Expenditures for Each Type of Cancer among US Adult Cancer Survivors (≥ 18 years) by Setting 
of Care and Polypharmacy for 2008, 2010, 2012, 2014 (N=10,580,285), ($US)  
 
 Breast Prostate Cervical Colon 
Setting No PP PP No PP PP No PP PP No PP PP 
Hospital  5,971   6,390   7,294  11,675  7,058  18,839  10,543  17,273  
Office-based 2,353   2,339  2,937   2,127  2,441  2,249    3,503  2,844  
Prescriptions 1,815  3,673* 2,038  3,486* 1,016  3,041*  1,786  6,249*  
Other medical 1,036  2,242*  1,294  1,854    1,238  1,015  1,505  4,955*  
Emergency room 1,676  1,363  2,737  2,405   1,522  1,735  1,136  1,018  
 Melanoma Leukemia/Lymphoma Other   
 No PP PP No PP PP No PP PP   
 16,922  7,709   8,742  19,144*  8,943  12,964*    
 2,725  2,837    4,016  3,605  2,296*  2,069    
 887  3,663*    852  2,313 * 1,463    4,178*    
 492  879   1,101  3,678  1,150  2,563    
 406  765 * 641  2,347*  1,689  3,330*   
Note: No PP = no polypharmacy; PP = polypharmacy. Hospital = inpatient or outpatient hospital-based 
expenditure. Emergency = Emergency Room. Prescriptions = prescription medications. Other medical = 
sum of spending for the following: dental care, vision care, home health agency (sponsored and paid 
independent providers), and other expenses not classified elsewhere. Estimates are adjusted for the 
following variables: age group, gender, race, region, number of provider encounters, marital status, 
comorbidity score, education level, poverty level, and insurance coverage. Gender was excluded from 
cervical, prostate, and breast cancer models. *= significantly increased expenditures compared within 
PP / No PP pairing at alpha = 0.05 significance. 
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Table 5. Unadjusted and Adjusted Regression Estimates (β) with Standard Errors (SE) of 
Significantly Associated Variables Based on an Ordinary Least Squares Regression Model with 
Log Transformed Expenditures for Patient and Clinical Factors in US Adult Cancer Survivors (≥ 
18 years) for 2008, 2010, 2012, 2014 (N=10,580,285). 
 
Studied Variables Unadjusted Model Adjusted Model 
Beta (SE) P value Beta (SE) Change 
(%) 
P value 
Polypharmacy 
     Yes 1.23 (0.04) <.0001 0.60 (0.05) 82.0 <.0001 
Age Group (years) 
     18-49  Reference 
     50-64 0.65 (0.08) <.0001 0.19 (0.06) 20.4 0.0014 
     65-74 0.77 (0.08) <.0001 0.04 (0.06) 4.6 0.4834 
     ≥ 75 0.87 (0.08) <.0001 0.08 (0.07) 8.7 0.2587 
Insurance Coverage 
     Private  Reference 
     Public 0.07 (0.06) 0.2467 -0.12 (0.04) -11.6 0.0023 
     Uninsured -1.15 (0.17) <.0001 -0.42 (0.14) -34.3 0.0029 
Type of Cancera 
     Breast 0.41 (0.12) 0.0008 0.20 (0.09) 21.8 0.0034 
     Cervical/other female genital 0.06 (0.16) 0.6948 0.21 (0.11) 23.4 0.0518 
     Colon/other gastrointestinal 0.71 (0.15) <.0001 0.57 (0.11) 76.3 <.0001 
     Leukemias and lymphomas 0.53 (0.18) 0.0033 0.40 (0.13) 48.7 0.0015 
     Other/unspecified 0.20 (0.12) 0.0834 0.21 (0.09) 23.9 0.0135 
     Prostate/other male genital 0.34 (0.12) 0.0057 0.27 (0.10) 31.1 0.0070 
     Melanoma Reference 
Elixhauser Comorbidity Index (no. of conditions) 
     0/None Reference 
     1  0.54 (0.08) <.0001 0.10 (0.06) 11.0 0.1014 
     2  0.83 (0.08) <.0001 0.14 (0.07) 15.2 0.0441 
     ≥ 3  1.38 (0.07) <.0001 0.31 (0.06) 36.8 <.0001 
Provider Encounters (no. of visits) 
     0 - 4  Reference 
     5 - 9 0.84 (0.07) <.0001 0.68 (0.07) 99.6 <.0001 
     10 - 19 1.54 (0.07) <.0001 1.23 (0.07) 247.8 <.0001 
     ≥ 20 2.30 (0.07) <.0001 1.85 (0.08) 547.1 <.0001 
Time since cancer diagnosis (years) 
     0-2 0.35 (0.08) <.0001 0.31 (0.08) 35.7 <.0001 
     3-5 Reference 
     6-10 0.07 (0.06) 0.2299 0.06 (0.07) 6.6 0.3618 
     >10 0.11 (0.05) 0.0287 0.03 (0.07) 2.9 0.6793 
Notes: aType of cancer included the following categorizations: prostate (included testicular cancer 
and cancer of other male genitals), cervical (included uterine, ovarian, other female cancers), 
colorectal (esophageal, stomach, colon, rectum and anus, liver and intrahepatic bile duct, pancreas, 
and other gastrointestinal cancers). Adjusted R2 value for final model equaled 0.46.  Model intercept 
equaled 7.05 (SE=0.12). 
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Table 6. Subgroup-Specific Smear Adjusted Mean Annual Direct Healthcare Expenditures, with 
or without Polypharmacy, in US Adult Cancer Survivors (≥ 18 years) for 2008, 2010, 2012, 2014 
(N=10,580,285). 
Polypharmacy 
Log 
Transformed 
Expenditure 
Estimate 
(ln(β)) 
Standard 
Error  
Retransformed 
Expenditure 
Estimate (expβ, 
$US) 
Subgroup-
Specific 
Smearing 
Factor 
Smear 
Adjusted 
Expenditure 
Estimate, 
($US) 
No 8.3930 0.05151 4,416 1.98199 8,753 
Yes 8.9916 0.05626 8,035 1.65097 13,266 
Note: Adjusted R2 value for final OLS model was 0.46. Mean differences of log transformed 
expenditure estimates was significant (p<.0001). The subgroup-specific smearing factors were 
calculated as the mean of the exponentiated residuals. Smear-adjusted expenditure estimate is the 
product of the retransformed expenditure estimate and the subgroup-specific smearing factor. 
Adjusted for age, type of cancer, insurance coverage, comorbidity score, time since cancer diagnosis, 
and number of provider encounters. 
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3.1 Abstract 
 
BACKGROUND:  Patients with cancer are particularly susceptible to polypharmacy 
(PP), which may increase the risk of developing health complications (HCs). The 
objective of this study was to evaluate the association between PP and nonfatal HCs 
among newly diagnosed patients with common cancer types in the United States (US). 
METHODS: We conducted a retrospective cohort study of de-identified, newly 
diagnosed adult (≥ 18 years old) breast, prostate, lung and colorectal cancer patients 
using the Optum Clinformatics® DataMart (Optum, Eden Prairie, MN, USA) 
administrative claims database, years 2010-2015. PP was defined as ≥ 5 distinct 
therapeutic classes of medications filled through an outpatient pharmacy in the first 
quarter following patients’ index cancer diagnosis. The dependent variable was 
nonfatal HCs (none vs. ≥ 1 event). HCs were grouped by clinically meaningful 
category: cardiovascular (CV), central nervous system and psychiatric (CNS), 
gastrointestinal (GI), hematologic (HEMA), metabolic (METB), skeletal (SKEL), and 
miscellaneous drug-related events (ADE). We used multivariable logistic regression 
(LR), with adjusted odds ratios (aORs) with 95% confidence intervals (CI) as the 
measure of effect to examine associations between PP and HCs in patients with cancer 
overall, and by type of cancer, controlling for demographic and physical and mental 
comorbid conditions. 
RESULTS: The analytic cohort consisted of 35,336 individuals with cancer (breast 
14,700, prostate 15,706, colorectal 3,292, and lung 1,638). PP was present in 14,573 
(41.2%) of individuals. Percentage of PP by type of cancer were: breast 42.7%, 
prostate 37.0%, colorectal 43.7%, lung 64.0%. Individuals with PP had higher rates of 
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HCs compared to those without PP: CV 19.2% vs. 8.9%, CNS 5.2% vs. 2.4%, GI 
2.8% vs. 1.6%, HEMA 9.9% vs. 5.5%, METB 3.8% vs. 1.1%, SKEL 5.6% vs. 3.5%, 
and ADE 3.0% vs. 1.4%, during follow-up. In the primary analysis, PP was associated 
with a 31% increased odds (aOR) of having ≥ 1 HCs, controlling for age, region, type 
of cancer, comorbidities, radiation and chemotherapy treatments. PP was significantly 
associated with a higher risk of having ≥ 1 HC in each cancer type (aOR: breast 1.37, 
95% CI: 1.31-1.42; prostate 1.27, CI: 1.22-1.32; colorectal 1.26, CI: 1.16-1.36; lung 
1.25, CI:  1.11-1.40). Active chemotherapy was associated with significantly increased 
odds of ≥ 1 HC in colorectal (aOR: 1.35, CI: 1.21-1.50) and lung (aOR: 1.33, CI: 1.15-
1.54) cancers, but not significantly associated with breast or prostate cancers.  
CONCLUSIONS: Newly diagnosed patients with breast, prostate, colorectal, or lung 
cancer with PP were all at a higher risk of having ≥ 1 nonfatal HCs as compared to 
those without PP. Active chemotherapy treatment was associated with increased risk 
of HCs in colorectal and lung cancer patients, but not in breast or prostate cancer 
patients. 
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2.2 Introduction 
 
PP is defined most commonly in the literature as the concomitant use of ≥ 5 
medications,1 and one study found that 80% of newly diagnosed elderly (≥ 65 years) 
cancer patients met this criterion.2 Patients with cancer often receive many 
medications,3 regularly exceeding the numerical threshold for polypharmacy (PP). 
Reasons for the multitude of prescribed medications in cancer patients are usually 
rooted in underlying chronic conditions occurring naturally with aging.4 For instance, 
32.2% of older women (> 66 years) newly treated for breast cancer have 
comorbidities.5 With the median ages at diagnosis for the four most common types of 
cancer in the United States (US) being 61 years for breast cancer, 68 years for 
colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer, comorbid 
conditions are common in this population.6 Comorbid conditions in patients with 
cancer can influence the treatment care planning.4 For example, women with breast 
cancer may not receive certain types of chemotherapy if comorbid conditions 
sufficiently increase the risk of complications.5# However, depending on stage of 
cancer and other factors, women may still receive additional medications such as 
hormone therapy or pain relievers, in addition to medicines they take for underlying 
conditions. 
 
Some cancer patients may, or may not, be using 5 prescribed medications at 
the time of their diagnosis. However, during the course of treatment for cancer, they 
may add new medications resulting in PP. One concern which arises from PP among 
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older patients is the increased risk associated with use of potentially inappropriate 
medications (PIMs) that may have a deleterious effect on the patient’s health. PP has 
been associated with PIMs previously.7,8,9 PIMs are concerning for cancer patients as 
one study found that, of newly diagnosed cancer patients who visited ambulatory 
oncology clinics, the odds of using PIMs increased by 18% for each additional 
medication in those defined as having PP (≥ 5 concomitant medications) compared to 
those without PP.10 Common cancer-related ailments such as pain, emesis, depression, 
venous thrombosis, and seizures can also necessitate additional medications.10  
 
The increased use of combinations of medications also increase the risk of 
drug-drug interactions (DDIs) among cancer patients, even among those not currently 
receiving antineoplastic treatments.1 DDIs can result in a lack of effectiveness of one 
or all the drugs, enhance toxicity, and diminish a treatment’s intended outcome.11 
Potential underlying risk factors for DDIs in cancer patients include mucositis and 
malnutrition causing impaired absorption, edema resulting from changes in a drug’s 
volume of distribution, or excretion changes from renal and/or hepatic dysfunction.12 
Other factors include a patient’s age, narrow therapeutic index of the drugs involved, 
and physiologic make-up.13 DDIs may lead to various negative outcomes, including 
new health complications among patients with cancer,13 and falls resulting in fractures 
which may cause delays in cancer treatments and alter the trajectory of the disease, 
care planning, or prognosis.14  
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A health complication (HC) is defined in this study similarly to an adverse 
event, as a possible negative outcome resulting in patient harm or injury due to use of 
prescribed medications,15 including medication errors, adverse drug reactions, allergic 
reactions, and overdoses.16  
 
To the authors’ knowledge, PP associated with HCs in newly diagnosed cancer 
patients have not been thoroughly investigated in a large administrative claims 
database. The primary objective of this study was to estimate and describe the 
frequency of HCs in newly diagnosed cancer patients, with or without polypharmacy, 
in a multivariable framework. 
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3.3 Methods 
 
Study design and data source 
 We conducted a retrospective cohort study to estimate the associated risk 
(odds) of having ≥ 1 health complication (HC) with PP among newly diagnosed adult 
cancer patients, controlling for various demographic attributes and clinical 
characteristics of those patients. The data source used was Optum Clinformatics® 
DataMart (Optum, Eden Prairie, MN, USA), years 2010-2015. The database contains 
de-identified claims information with the following data tables: eligibility of privately-
insured members, medical inpatient and outpatient professional services, inpatient 
services, outpatient prescription dispensings, and inpatient facility details. Patients 
were linked through a common identifier across the various claims tables to ensure all 
encounters are captured. The database is comprised of approximately 35 million 
unique commercially-insured patients in the US and their captured medical 
encounters.  
 
Sample selection 
 The study population included adult individuals (≥ 18 years old) with an 
incident diagnosis of cancer (breast, prostate, colorectal, and lung) who had 
continuous enrollment in medical and prescription insurance throughout a 12-month 
lookback period through the end of follow-up for the first year following cancer 
diagnosis. Female breast, prostate, colorectal, and lung cancer cases were selected for 
our study because they are considered the four major cancers by the American Cancer 
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Society.14 A patient had to have at least 2 cancer diagnosis claim codes (including in 
situ and metastasis), defined by the International Classification of Diseases, 9th 
Edition, Clinical Modification (ICD-9-CM) classification system, in the primary or 
secondary diagnosis field, which were at least 30 days apart in either the outpatient or 
inpatient setting (Appendix E). The patient’s first cancer diagnosis was their index 
date. Patients with claims of a personal history of cancer within one year prior to their 
first ICD-9-CM code matching were excluded from the algorithm. Individuals were 
excluded if their incident diagnosis was not between January 1, 2011 and September 
30, 2014. Men with breast cancer were excluded because the focus was on the four 
most commonly occurring cancers in the US. If an individual did not have any 
pharmacy claims in the year of follow-up they were excluded. People with more than 
one type of cancer were excluded, except those with metastatic codes to capture 
advanced stage diagnoses. Patients with less than one full year of data following 
incident diagnosis were excluded, including those who died. Figure 1 shows the 
inclusion and exclusion criteria in greater detail. 
 
The key independent variable (IV) of interest was PP, defined as a patient 
filling ≥ 5 distinct medication classes at an outpatient pharmacy in the first quarter (3 
months) following incident cancer diagnosis, not accounting for overlap or switching, 
with a cumulative sum of days’ supply of at least 7 days, during the 3-month exposure 
window after the index date. Since no clear definition of PP exists in the literature,2 we 
chose our definition based on published literature which used distinct therapeutic 
classes.17,18 These factors, coupled with other research which stated that no single cut-
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point was optimal in defining PP in cancer patients,19 but that ≥ 5 daily medications 
was a reasonable threshold for predicting multiple adverse events in elderly cancer 
patients, informed our decision to use ≥ 5 therapeutic classes as our threshold for PP. 
However, to examine medication use with more accuracy and in a shorter time period 
than the aforementioned study, we used a claims database study. Medication classes 
were categorized using the American Hospital Formulary Service (AHFS) 
Pharmacologic-Therapeutic classification system.20 Vaccinations, due to one-time 
administrations, and vitamin (A-E), due to their tendency to be more over-the-counter, 
medication classes were excluded from this definition.21 
 
Dependent variable 
 The primary outcome variable of interest was nonfatal health complications 
(HCs), and was dichotomized to either 0 (zero) HCs or ≥ 1 HC. HCs consisted of both 
specifically coded adverse drug-related events (ADEs) and other health conditions that 
are often associated with adverse effects of medications (e.g. organ toxicity, blood 
dyscrasias, falls). HCs were grouped into the following clinically meaningful 
categories: cardiovascular (CV), central nervous system and psychiatric (CNS), 
gastrointestinal (GI), hematologic (HEMA), metabolic (METB), skeletal (SKEL), and 
miscellaneous adverse drug-related events (ADE). The categories were curated from 
published literature based on their relevance to patients with cancer, PP, or both.22,23 
The outcomes selected were based on current literature and have been either (1) well 
documented in cancer patients,15,22,23,24,25,26,27,28,29,30,31 and/or (2) were considered more 
likely in people with PP.32,33,34,35,36 The goal of choosing these outcomes was to 
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provide a selective list of short-term events which could have been precipitated by the 
combination of drugs in a population with a lowered immune system, mostly elderly  
(≥ 65), and who may have been increasing their medications due to anticancer 
treatment. Clinical events related to common drug interactions in one study included 
deep vein thrombosis, upper digestive hemorrhage, various other forms of bleeding, 
and neutropenia.15 Other studies mentioned the risk of falling in elderly due to PP,47 or 
in those with cancer because of the risk to treatment delays and potential cancer-
related outcomes as a result.30,33 Other examples of specific HCs include fractures and 
arrhythmias (See appendix H for full list). HCs were measured in patients with cancer 
by using a claims-based algorithm searching for these complications using ICD-9-CM 
diagnosis codes. As part of the inclusion criteria, patients had to have continuous 
enrollment in both medical and prescription claims for the year following their 
incident diagnosis, thus they were alive throughout follow-up. The follow-up period in 
which these HCs were measured was during the 3 quarters following the exposure 
period (quarter 1) in which the presence of PP was determined.  
 
 Covariates 
Demographic covariates were assessed during the 12-month baseline period 
and included age, sex, and geographic region. Clinical variables assessed at baseline 
included type of cancer, insurance plan-type, and Elixhauser comorbidity score. 
Radiation and chemotherapy treatments were assessed after exposure. Cancer type was 
grouped in the following manner: breast (female only), prostate, lung, and colorectal 
using the ICD-9-CM codes listed in Appendix E. We chose to use the Elixhauser 
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comorbidity score, excluding the 3 codes related to cancer, to assess physical and 
mental diseases and disorders based on the variety of ailments contained within, and 
its well-established validity.37 The Elixhauser comorbidity score is the summation of 
various comorbid conditions which are dichotomized to represent a condition’s 
presence (1) or absence (0) (Appendix F). We categorized the scores based on the 
overall distribution into 3 categories 0, 1-2, ≥ 3 conditions. Patients with both 
complicated and uncomplicated diabetes, or hypertension, diagnoses claims were 
assumed to have the more complicated stage of the disease for these analyses. This 
method was used to prevent double counting of the disease if a patient had both 
claims. Anticancer infusions and injections were identified using Healthcare Common 
Procedure Coding System (HCPCS) coding system in the outpatient setting (J codes 
J8500-J9999). The HCPCS coding system classifies similar medical products into 
categories for efficient claims processing.38 If the individual received either an 
outpatient pharmacy prescription and/or a J code for an antineoplastic agent during the 
year following their incident diagnosis, they were defined as receiving active 
chemotherapy. Radiation was defined through Current Procedural Terminology (CPT) 
and HCPCS G codes (Appendix G).39,40  
 
 
Statistical analysis 
Descriptive statistics were used to describe the proportions of cancer patients 
by PP for each covariate. Chi-square tests were used to determine the statistical 
significance between PP and categorical covariates, as well as between PP and HCs. 
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Also, the percentages of PP in patients with a HC were described according to the type 
of cancer. Lastly, to provide information on the number and percent of different 
medication drug classes filled by those with or without PP, the 20 most filled 
medication drug classes were described. 
 
Logistic regression (LR) modeling was used to examine associations between 
individual covariates and HCs. Variables which had statistically significant (p-value 
<0.10) association with both PP and HC were used in the multivariable LR modeling 
process. The multivariable LR model examined the relationship between PP and HCs, 
controlling for the covariates which were significantly related to both PP and HC in 
the univariate LR models. Collinearity amongst covariates was assessed by examining 
the condition indices and variance decomposition proportions.41 However, no two 
independent variables were collinear and thus no variables were removed at this stage.  
 
Covariates were added to the model sequentially based on their negative 2 Log 
Likelihood statistic (-2 Log L). Model comparisons were assessed through the 
Likelihood Ratio Test (LRT) which produced comparison statistics among models 
based on their intercept and covariates using the -2 Log L, where a better fitting model 
had a lower -2 Log L value.41 A manual stepwise elimination process was used to 
remove variables with p-values higher than 0.05 significance to determine which of 
the remaining variables were still significant in the multivariable model.  Lastly, 
comparison between model performance were assessed by changes in Akaike 
Information Criteria (AIC), and goodness-of-fit was tested by changes in c-statistic 
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(concordance index) values.42 The measure of effect was the adjusted odds ratio (aOR) 
comparing the risk (odds) that a person having PP experienced a HC versus those 
without PP, controlling for all other significant covariates.  
 
The objective of a secondary analysis was to examine the relationship among 
PP with HCs by type of cancer, controlling for significant covariates (Table 3). To 
understand the relationship, four models were created (one for each cancer type) by 
first including the following covariates: sex (only for colorectal and lung cancers), 
age, region, insurance, comorbidity score, radiation therapy, and chemotherapy 
treatment. In these analyses, a manual backward elimination process was used to 
remove covariates that were not significant. First, the variable with the largest p-value 
(> 0.05) was removed. Next, the model was reanalyzed to determine if any of the 
remaining covariates became or remained insignificant. If a variable was insignificant 
(p-value >0.05) it was removed. This process was continued until only significant 
variables remained in the model. All statistical analyses were conducted using SAS 
software, version 9.4 (SAS Institute Inc., Cary, NC, USA). 
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3.4 Results 
 
The analytic cohort consisted of 35,336 adult cancer patients (Figure 1). Of 
these, 14,573 (41.2%) adults were defined as having PP in the first quarter following 
incident cancer diagnosis (Table 1). The cohort had the following characteristics: men 
(51.2%), ≥ 65 years (61.8%), were not actively on chemotherapy (68.3%) or radiation 
therapy (79.8%) and had ≥ 1 comorbid condition (68.8%). Of those with PP, 70.5% 
were ≥ 65 years, 52.5% were women, 43.1% had breast cancer, 37.4% were on 
chemotherapy, 19.9% received radiation therapy and 42.2% had ≥ 3 comorbid 
conditions (Table 1). In total, 8,891 (25.2%) people with cancer had ≥ 1 HC in the 
follow-up period (Table 1). Of those, 4,963 (34.1%) had at least 1 HC in the 3 quarters 
during follow-up. 
 
The proportion of adult cancer patients with PP and ≥1 HC as compared with 
those who did not have PP were significantly higher (p-value < .0001) across all HC 
groups (Table 1). The proportion of patients with PP and ≥ 1 cardiovascular (CV) 
event was 19.2% compared to patients without PP who had ≥ 1 CV event (8.9%). The 
other differences in proportions were as follows: CNS 5.2% vs. 2.4%, GI 2.8% vs. 
1.6%, HEMA 9.9% vs. 5.5%, METB 3.8% vs. 1.1%, SKEL 5.6% vs. 3.5%, and ADE 
3.8% vs. 2.4%, per year during follow-up. All counts and percentages for this analysis 
are presented in Table 1. All differences were statistically significant at the alpha = 
0.05 level. 
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Prescription medications 
 A total of 155,735 prescriptions were filled during the exposure window 
(Table 2). Of those, 107,619 (69.1%) were filled by those defined as having PP. The 
20 most filled medication classes amounted to 63.9% of total fills for those without PP 
compared with 54.4% in the PP group. The classes of medications were similar in both 
groups, with HMG-CoA reductase inhibitors being filled the most for PP (7.3% of fills 
for PP) and no PP (9.8% of fills for No PP). For the 20 most filled medications, 
differences existed between those with and without PP for a handful of classes. For 
example, loop diuretics (1.7%), sulfonylureas (1.6%), anticonvulsants (1.6%), and 
metformin (1.5%) were top 20 filled medications by people with PP, but not those 
without PP. Conversely, first generation cephalosporins (2.0%), corticosteroids 
(1.4%), aminopenicillins (1.3%), and anti-inflammatory (skin) agents (1.2%) were in 
the top 20 for those without PP, but not those with PP. 
 
Health complications 
Figure 3 highlights percentage of patients with ≥1 HC by type of cancer, with 
or without PP. Regardless of cancer type, patients with ≥1 HC had a higher percentage 
of PP. Patients with lung cancer and HCs had the highest percentage of PP (73.1%). 
Conversely, men with prostate cancer and ≥1 HC had the lowest percentage of PP 
(51.2%). 
  
 Presented in Figure 4 are the percentages of HCs by PP for each type of 
cancer. Across each type of cancer CV complications occurred the most, with HEMA 
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HCs as the second most frequent. Differences between PP and no PP groups were 
statically significant at p-value < 0.05 for each cancer type, with the exception of GI in 
colorectal and lung, and skeletal in lung. 
 
Primary analysis: association between PP and nonfatal HCs 
To determine the association between PP and nonfatal HCs in the analytic 
cohort, a multivariable LR model was created controlling for age, region, type of 
cancer, comorbidity burden, radiation therapy, and chemotherapy (Figure 4). Excluded 
from this analysis were sex (due to the gender-specific nature of breast and prostate 
cancers) and insurance type (due to its insignificance during the model building 
process described in the Methods section). PP was associated with a 31% increase in 
the risk of having ≥ 1 HC (aOR 1.31, 95% CI: 1.27-1.35, p-value <.0001) in the 
follow-up period when controlling for the covariates. Breast and prostate cancers were 
significantly associated with decreased risk of having ≥ 1 HC compared to colorectal 
cancer (aOR 0.83, 0.79-0.87, p-value <.0001 and aOR 0.84, 0.81-0.87, p-value <.0001 
respectively). Whereas lung cancer had a significantly increased risk for ≥ 1 HC 
compared to colorectal cancer (aOR 1.23, 1.13-1.23, p-value <.0001). 
 
Chemotherapy and radiation treatments were both significantly associated with 
a slightly increased risk of having ≥ 1 HC in the final multivariable LR model (aOR 
1.07, 1.03-1.10, p-value <.0001 and aOR 1.06, 1.02-1.10, p-value= 0.0012, 
respectively). Age ≥ 75 years old was significantly associated with an increased risk of 
having the outcome of interest compared to those aged 50-64 years (aOR 1.39, 1.33-
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1.45, p-value <.0001). The Northeast was significantly associated with an increase in 
risk of having ≥ 1 HCs compared to those in the Midwest (aOR 1.08, 1.02-1.14, p-
value= 0.0088). Figure 4 presents additional results pertaining to comorbidity level 
and use of chemotherapy or radiation.  
 
Secondary analysis: associations between PP and HCs by type of cancer  
Four multivariable logistic regression models were created to assess the 
association between PP and HCs for each type of cancer (Table 3). As mentioned 
previously, sex was excluded as an explanatory variable from the analysis for breast 
and prostate cancers, due to those cancers being sex-specific. Across all four models 
PP, age, and comorbidity were significant predictors of HCs. The association between 
PP and ≥ 1 HC and other main findings by type of cancer are described next.  
 
In the model for women with breast cancer, PP was associated with a 37% 
increase in the odds of having ≥ 1 HC in the follow-up period (aOR 1.37, 1.31-1.42, p-
value <.0001) compared to those without PP. Each age group was significantly 
different from those aged 50-64 years old, with the oldest having a 26% increase in 
risk (aOR 1.26, 1.17-1.35, p-value <.0001). The West was the only region 
significantly different from the Midwest and associated with a decreased risk of 
having ≥ 1 HC by 18% (aOR 0.82, 0.77-0.88, p-value <.0001). The number of 
comorbid conditions and radiation therapy were significant, but chemotherapy was not 
(Table 3). 
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In the model for prostate cancer, PP was associated with a 27% increase in the 
risk of having ≥ 1 HC (aOR 1.27, 1.22-1.32, p-value <.0001). Younger age (18-49 
years) was associated with a 35% decreased risk of ≥ 1 HC (aOR 0.65, 0.51-0.83, p-
value = 0.0004); whereas the oldest aged group (≥ 75 years) had a significantly higher 
risk (aOR 1.71, 1.55-1.88, p-value <.0001) compared to those aged 50-64 years. Each 
region was significantly different from the Midwest, with the Northeast associated 
with an increased risk of ≥ 1 HC (aOR 1.12, 1.02-1.23, p-value = 0.0143). Similar to 
breast cancer, chemotherapy was not significantly associated with HCs. Unlike breast 
cancer, radiation therapy was insignificant. Table 3 includes findings for age, region, 
comorbidity level, chemotherapy, and radiation. 
 
PP was associated with 26% increase in the risk of having ≥ 1 HC (aOR 1.26, 
1.16-1.36, p-value <.0001) in people with colorectal cancer when controlling for age, 
region, comorbidities, and chemotherapy. Unlike breast and prostate cancers, 
chemotherapy was significantly associated with an increased risk of having the 
outcome of interest for those with colorectal cancer (aOR 1.35, 1.21-1.50, p-value 
<.0001). Age followed the same pattern as prostate cancer, where younger age was 
associated with a decreased risk of having ≥ 1 HC (aOR 0.61, 0.49-0.75, p-value 
<.0001), and older age was associated with an increased risk (aOR 1.73, 1.52-1.97, p-
value <.0001). Table 3 includes findings for age, sex, region, comorbidity level, 
chemotherapy, and radiation. 
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Lastly, for those with lung cancer, PP was associated with a 25% increased risk 
of ≥ 1 HC (aOR 1.25, 1.11-1.40, p-value =0.0002). Unique to those with lung cancer 
was the significant increased risk associated with the person’s sex. Men were 22% 
more likely to have ≥ 1 HC compared to women (aOR 1.22, 1.10-1.36, p-value = 
0.0002). Both chemotherapy (aOR 1.33, 1.15-1.54, p-value <.0001) and radiation 
treatment (aOR 1.25, 1.10-1.36, p-value = 0.0188) were associated with increased 
odds of having ≥ 1 HC. Unlike the other cancer types, the analyzed regions were not 
associated with a significant difference in risk for people with lung cancer compared 
to the Midwest. Model fit (c-statistic) values for each are presented in the notes section 
at the bottom of Table 3.  
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3.5 Discussion 
 
We used a large administrative claims database to describe the association 
between PP and the risk of having ≥ 1 HCs among newly diagnosed patients with 
breast (female), prostate, lung, and colorectal cancer controlling for significant 
covariates (age, sex, radiation therapy, chemotherapy, comorbid conditions, and 
geographic region). We also estimated associations between each type of cancer and 
HCs controlling for those covariates. In each multivariable LR model, PP was 
associated with a greater than 25% increase in the risk of having ≥ 1 HC. 
 
Polypharmacy 
In our study, we found that greater than 40% (2 in 5) of adult patients with 
newly diagnosed breast, prostate, colorectal, and lung cancers were defined as having 
PP in the first quarter following diagnosis. One study, which defined PP as ≥ 5 distinct 
medications, reported the prevalence of PP to be 64% in cancer survivors; however, 
this was a cross-sectional study with a more liberal definition of polypharmacy, which 
summed the medications used over two years.43 Three studies reported the overall 
prevalence of PP in newly diagnosed cancer patients to be 80% (patients aged ≥ 65 
years in US),3 57% (in patients aged ≥ 70 years in Australia),44 and 35% (patients also 
≥ 70 years in Denmark).45 However, all studies varied in their setting and collection 
methods. In the study that reported overall PP of 35%, lung cancer had the highest 
percentage of patients with PP (40.9%), compared to the other types of cancer: 32.9% 
(breast), 29.9% (colorectal), and 32.3% (prostate).45 These rates were slightly lower 
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than our results; however, that study was a case-control study where the controls did 
not have a cancer diagnosis at the index date. Although we did not have the same 
study design or source population, our results showed that PP, by type of cancer, was 
also highest in patients with lung cancer (64.0%).  
 
PP was associated with a significantly higher risk of having ≥ 1 HC in all 
analyses, including unadjusted and adjusted LR models. By grouping HCs, we found 
that cancer patients with PP had higher proportions of HCs for different body systems 
compared to those without PP. For example, complications involving the 
cardiovascular system were more than double (19.2%) in patients with PP compared to 
those without PP (8.9% p-value <.0001). A study by Barber et al found that certain 
hormone therapies in breast and prostate cancer patients increased cardiac 
arrhythmias.24 In a review of the impact chemotherapy has on cardiac arrhythmias, 
Tamargo et al reported inducement of a direct cardiac effect that can also be initiated 
or maintained by substrates created by comorbid conditions or the chemotherapy.25  
Hematologic HCs were the second most common, with 9.9% of patients with PP 
having at least one compared to 5.5% in those without PP. The hematologic HCs 
included in this study are well-established outcomes in patients with cancer; especially 
venous thromboembolisms and pulmonary embolisms which are known to increase 
after surgery and chemotherapy treatment.26  
 
The results of the primary analysis showed that PP was highly significant in its 
association with the risk of having HCs by 31% when controlled for age, region, type 
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of cancer, comorbidity, chemotherapy, and radiation therapy. This means that patients 
with PP, which comprise 40% of those newly diagnosed with the four most common 
types of cancer, have a 31% higher risk of health complications overall. Polypharmacy 
has been associated with increased use of potentially inappropriate medications, which 
can cause adverse health outcomes among older patients. According to a study by 
Lund et al, which analyzed the Surveillance, Epidemiology, and End Results (SEER)-
Medicare database, among 19,318 breast, 7,283 colon, and 7,237 lung cancer patients 
age 66 years and older, the number of PIMs changed after initial diagnosis of cancer 
during follow-up (6-23 months duration).27 The increase in PIM dispensing was 
directly related to chemotherapy initiation in the first six months. They reported that 
for women with breast cancer PIMs decreased, while those with colon or lung cancer 
saw an increase. In our analysis, a decreased aORs for breast cancer patients, and 
increased aORs for lung, compared to the reference group (colorectal cancer) may be 
caused by a similar PIM risk. Lund et al did not study prostate cancer, but with the 
watchful-waiting or active surveillance approach recommended by the National 
Comprehensive Cancer Network (NCCN), a lack of additional medications for 
treatment may also decrease the risk of PIMs and thus decrease the odds of HCs.46 
 
The secondary analysis of PP among cancer types revealed cancer-specific 
differences for PP and some of the covariates. PP had the largest estimated risk in 
breast cancer patients of the four main cancers, with an increased risk of 37%. One 
explanation for this may be the influence of the covariates, specifically that 
chemotherapy was not significantly associated with HCs. Lund et al found that of 
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19,318 newly diagnosed patients with stage I-III breast cancer, PIMs declined (40% to 
34%) after diagnosis and leveled off as chemotherapy use was curtailed beginning 3 
months after incident diagnosis until 23-months follow-up.27 For women with early 
stage breast cancer, they often receive surgery followed by radiation then hormone 
therapy, but not chemotherapy.47 According to Edwards et al, women with any number 
of comorbid conditions are less likely to receive chemotherapy compared to those who 
have none.48 Therefore, for the women who receive chemotherapy, they may have an 
advanced stage of breast cancer, and the risk of complications would not be 
significantly different. Our results showed that women between the ages of 65 and 74 
years had a lower risk of HCs compared to those 50-64 years and this lack of 
chemotherapy may be why. As chemotherapy is not recommended for early stages of 
breast cancer in adults over 70,48 or with having a high number of comorbidities, our 
findings suggest that these newly diagnosed breast cancer patients were in situ or 
invasive, but not metastatic. Whereas, those aged ≥ 75 years had the highest number of 
comorbid conditions (38.5%: not shown) compared to the reference group which had 
the largest percentage without comorbidity (35.5%: not shown). Also, radiation 
therapy was associated with more HCs which is logical since side-effects linked to 
radiation therapy may lead to exacerbating underlying conditions. The youngest age 
group was associated with a higher risk for HCs, which could be explained by 58% 
(not shown) of those aged 18-49 having no comorbidities, indicating they may have 
had a more aggressive form of cancer, as 59% of those aged 18-49 received 
chemotherapy treatment compared to 56.0% in the reference group. This higher rate of 
chemotherapy may have directly led to an increase in HCs. 
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Patients with prostate cancer and PP had a 27% increased risk of having ≥ 1 
HC when controlling for age, region, and comorbidity score. Like patients with breast 
cancer, chemotherapy was not significantly different between those who had ≥ 1 HC 
and those who had none during follow-up. One explanation would be that men with 
prostate cancer tend to be diagnosed in their late 60s and early 70s, and the median age 
in this study was 69 years. Standard of care for patients with low-risk prostate cancer 
thus does not usually involve chemotherapy but may include hormone therapy. 
Radiation therapy was also not significantly associated with the outcome of interest. 
Differences in HCs from those 50-64 years old were also significant for those 18-49, 
but in prostate cancer younger age was protective (35% decrease in risk) because 
younger people, on average, had fewer comorbidities (43.4% of 18-49 had none 
compared to 31.7% in 50-64, 25.1% in 65-74, and 28.7% in ≥75) . Whereas those aged 
65-74 were not significantly different than the reference group, but those ≥ 75 were 
significantly associated with an increased risk (71%) for HCs.  
 
Patients with colorectal cancer and PP had a 26% increase in risk of having ≥ 1 
HC. Unlike breast and prostate cancer, colorectal cancer occurs in both men and 
women. However, in the analysis men and women did not significantly differ in risk 
for the outcome. As with prostate cancer, younger age (18-49) was associated with a 
decreased risk (39%) and older age with increased risk (73%) of HCs. Also differing 
from breast and prostate cancer patients, chemotherapy was associated with an 
increased risk of HCs (35%). One explanation for the lowered risk in younger people, 
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despite an increased risk associated with chemotherapy, could be that younger people 
had the lowest number of comorbidities (34.1% had none in 18-49 years old) 
compared to the referent age group (25.5%). Conversely, 75% of those ≥ 75 years had 
at least 1 comorbid condition.  
 
PP was associated with a 25% increase in risk for the outcome in patients with 
lung cancer after controlling for sex, age, comorbidity, chemotherapy, and radiation. 
Men had a 22% higher risk for having ≥ 1 HC than women. Again, since men smoke 
more and have shorter life spans in general than women, so at the advanced age when 
being diagnosed with lung cancer we would expect men to have a greater risk for HCs. 
Both chemotherapy and radiation were significant. We would expect this to be the 
case since most lung cancers are diagnosed at a late stage.49 Although surgery may be 
undertaken in limited scope, treatment often relies on chemotherapy and radiation to 
eliminate the disease. Having 3 or more comorbid conditions compared to no 
conditions increased the risk by 69%. Comorbid conditions such as COPD and 
emphysema are known to occur in people with lung cancer at diagnosis, which would 
increase the risk of having HCs. 
 
We also noted differences in the association between HC events and type of 
cancer in the final multivariable LR model. In breast and prostate cancer patients, 
results showed these cancer types were less likely to have a HC compared to 
colorectal or lung cancer, and may be explained, in part, by the status of chemotherapy 
treatment. Being on chemotherapy treatment in both breast and prostate cancers was 
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not significantly associated with HCs in their respective models (Table 2). In one 
study, which measured drug-related problems (DRP) (e.g. inappropriate drug, adverse 
drug reaction) in elderly (mean age 71.1 years) cancer patients, 77.6% were taking ≥ 3 
chronic medications concurrently with intravenous chemotherapy and reported to have 
an average incidence of 3 DRP.31 Interestingly, adverse drug reactions were reported 
to be caused by chemotherapeutic agents 85% of the cases; whereas, potential drug-
drug interactions were related to chronic use medications 92.6% of the cases.31 Similar 
to this analysis, the study on drug-related problems found a statistically significant 
increase in the odds of having a DRP when taking ≥ 5 medications.31 However, 
intensity and duration of chemotherapy were unmeasured confounders in the analysis.  
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3.6 Limitations 
 
Although efforts were made to address temporality by defining PP in the 1st 
quarter following incident diagnosis, no assurances can be made that the individual 
was actively taking the medication preceding the event, or that any combination of 
medications directly caused the event to occur. Also, although comorbid conditions 
were controlled for with a summary score, no assessment was made in baseline to 
assess if the HCs were incident cases, thus allowing for the HCs to be chronic in 
nature. Further research is warranted that would focus more closely on individual 
cancers and HCs resulting from concomitant use of medications. 
 
As with any administrative database analysis, the underlying data may lead to 
misclassification of some individual’s cancer or comorbid status. Neither severity nor 
stage of cancer are included within the database as standalone variables, and hence 
were not controlled for in the analyses. As such, determination of stage or grade of 
cancer was not possible. Stage or grade of tumor would be a critical confounding 
variable, as these would determine the course of action for these patients regarding 
surgery, chemotherapy, and radiation treatments. 
 
We were unable to conduct any analyses regarding race, as we did not have 
this variable in the database. Incidence rates for the four most common cancers studied 
in this manuscript vary by race. For instance, African Americans have higher 
incidence rates for prostate, colorectal, and lung cancers compared to White, Hispanic, 
and other racial/ethnic groups.50  
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Intensity of infusion chemotherapy nor strength or dosing of prescription 
anticancer agents were analyzed for this analysis. The definition used to classify a 
newly diagnosed cancer patient as PP was based on the number of distinct medication 
classes and a minimum days’ supply during the first quarter following diagnosis. This 
definition inherently may lead to under- or overestimation of the number of patients 
with PP because most adherence rates for chronic medications would require reaching 
80% adherence. Some definitions of PP have counted individual medications, 
including counting infusions over their day of activity, which would mean counting 
them more than once per month to account for administration cycles. Also, we did not 
account for infusions or injections which may have not been related to anticancer 
treatment. The focus of defining PP was for outpatient pharmacy filled medications 
and therefore inpatient drug usage, over-the-counter, and complementary and 
alternative drugs were not included as potential contributors to PP in this analysis.  
Although medications were described in this analysis, no formal statistical tests were 
conducted to assess associations between their concomitant use and HCs. We 
examined common HCs associated with PP and cancer patients. The study was 
designed to use medication class because the mechanism of action within drug class 
would be the same despite different ingredients.  
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3.7 Conclusions 
 
Newly diagnosed patients with breast, prostate, colorectal, or lung cancer who 
had PP were all at a higher risk of having ≥ 1 health complication compared to those 
without PP. When analyzing by type of cancer and controlling for age, sex, 
comorbidity, chemotherapy and radiation therapy, PP was associated with an 
increased risk of HCs by over 25% per cancer type. Active chemotherapy treatment 
was associated with increased risk of HCs in colorectal and lung cancer patients, but 
not in breast or prostate cancer patients.  
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Figure 1. Selection of Patients for Analyses of Health Complications in Adults (≥ 18 years) Newly 
Diagnosed with Cancer, with or without Polypharmacy, in Optum Clinformatics Data Mart 2011-
2014. 
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Figure 2. Study Window Timeline (not to scale) 
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Table 1. Demographic and Clinical Characteristics of Adults (≥ 18 years) with Newly Diagnosed 
Cancer by Polypharmacy Status During 2011-2015, (N= 35,336). 
Demographic and Clinical 
Characteristics of Cancer 
Survivors 
No Polypharmacy Polypharmacy 
p-value 
(N= 20,763 | 58.8 %) (N= 14,573 | 41.2 %) 
Age group (years) 
<.0001 
     18-49 2,014 (9.7)  688 (4.7) 
     50-64 7,189 (34.6) 3,618 (24.8) 
     65-74 6,525 (31.4) 5,142 (35.3) 
     ≥ 75 5,035 (24.3) 5,125 (35.2) 
Sex 
<.0001      Men 11,164 (53.8) 6,926 (47.5) 
     Women   9,599 (46.2) 7,647 (52.5) 
Region 
<.0001 
     Northeast 2,099 (10.1) 1,384 (9.5) 
     South 7,531 (36.3) 5,514 (37.8) 
     Midwest 4,287 (20.6) 2,731 (18.7) 
     West 6,846 (33.0) 4,944 (34.0) 
Insurance Coverage 
<.0001 
     Commercial 10,439 (50.3) 9,775 (67.1) 
     Medicare Advantage 10,324 (49.7) 4,798 (32.9) 
Type of Cancera 
<.0001 
     Breast (female) 8,422 (40.6) 6,278 (43.1) 
     Prostate 9,898 (47.7) 5,808 (39.9) 
     Colorectal 1,854 (8.9) 1,438 (9.9) 
     Lung 589 (2.8) 1,049 (7.2) 
Chemotherapyb  
<.0001      Yes 5,764 (27.8) 5,453 (37.4) 
Radiation Therapy 
0.2862      Yes 4,235 (20.4) 2,905 (19.9) 
Elixhauser Comorbidity Score (baseline)c 
<.0001 
     0 8,318 (40.1) 2,703 (18.6) 
     1-2 9,336 (44.9) 5,721 (39.3) 
     ≥ 3 3,109 (15.0) 6,149 (42.2) 
Health Complication (HC)d  
     Cardiovascular 1,857 (8.9) 2,794 (19.2) <.0001 
     CNS and Psychiatrice 495 (2.4) 759 (5.2) <.0001 
     Gastrointestinal 333 (1.6) 410 (2.8) <.0001 
     Hematologic 1,133 (5.5) 1,449 (9.9) <.0001 
     Metabolic 236 (1.1) 559 (3.8) <.0001 
     Skeletal 725 (3.5) 812 (5.6) <.0001 
     Adverse drug-related event 297 (1.4) 430 (3.0) <.0001 
Patients with any HC 3,928 (18.9) 4,963 (34.1) <.0001 
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Notes: aCodes used to define each type of cancer are in Appendix E.  
bChemotherapy was dichotomized into two groups based on absence or presence of at least 1 
outpatient prescription claim using American Hospital Formulary System (AHFS) of classification 
coding or a Healthcare Procedure Coding System Level II (HCPCS) in the range of J8500-J9999 in 
the follow-up year post-index claim.  
cElixhauser Comorbidity Score is the summation of a dichotomized variable for absence or 
presence of various health conditions found in Appendix F. In this analysis, 4 of the original 31 
disease (states) coding groupings were excluded as 3 related to cancer conditions and 1 related to 
an outcome of interest (arrhythmias). Baseline refers to the time from the index date (first cancer 
diagnosis) up to 365 days prior to the index date. 
dCode sets for health complications (HCs) are in Appendix G. HCs were assed in the 2nd, 3rd, and 
4th quarter following a patient’s incident cancer diagnosis. 
eCNS= central nervous system. 
 
  
116 
 
Table 2. The 20 Most Filled Prescription Medication Classes During the Exposure Window for 
Cancer Patients, by Polypharmacy, N,% (N=35,336). 
No Polypharmacy Polypharmacy 
Medication Class N %  Medication Class N % 
 
HMG-CoA reductase inhibitors 4,492 9.8 HMG-CoA reductase inhibitors 7,816 7.3 
Angiotensin-converting enzyme 
inhibitors 
3,047 6.7 
Beta-adrenergic blocking agents 5,686 5.3 
Beta-adrenergic blocking agents 2,312 5.1 Angiotensin-converting enzyme 
inhibitors 5,109 4.8 
Antineoplastic agents 2,299 5.0 Dihydropyridines 3,617 3.4 
Dihydropyridines 1,748 3.8 Proton-pump inhibitors 3,614 3.4 
Opiate agonists 1,613 3.5 Opiate agonists 3,508 3.3 
Angiotensin ii receptor 
antagonists 
1,483 3.3 Angiotensin ii receptor 
antagonists 2,754 2.6 
Thyroid agents 1,431 3.1 Antineoplastic agents 2,722 2.5 
Proton-pump inhibitors 1,346 3.0 Thyroid agents 2,605 2.4 
Selective alpha-1-adrenergic 
block.agent 
1,339 2.9 
Metformin 2,589 2.4 
Quinolones 1,199 2.6 Selective-serotonin reuptake 
inhibitors 2,468 2.3 
Selective-serotonin reuptake 
inhibitors 
954 2.1 
Quinolones 1,993 1.9 
Other nonsteroidal anti-inflam. 
agents 
937 2.1 
Loop diuretics 1,869 1.7 
First generation cephalosporins 899 2.0 Benzodiazepines 
(anxiolytic,sedativ/hyp) 1,847 1.7 
Benzodiazepines 
(anxiolytic,sedativ/hyp) 
847 1.9 Selective alpha-1-adrenergic 
block.agent 1,844 1.7 
Thiazide diuretics 808 1.8 Other nonsteroidal anti-inflam. 
Agents 1,773 1.7 
Metformin 645 1.4 Sulfonylureas 1,710 1.6 
Corticosteroids (eent) 616 1.4 Anticonvulsants, miscellaneous 1,683 1.6 
Aminopenicillins 572 1.3 Thiazide diuretics 1,675 1.6 
Anti-inflammatory agents (skin, 
mucous) 
560 1.2 
Other diabetes* 1,633 1.5 
Notes: Total number of unique prescription classes filled for those without PP and those with PP 
were 48,116 and 107,619, respectively. 
*= drug class name was diabetes mellitus, but to not confuse it with biguanides (metformin) they are 
listed as Other diabetes. 
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Figure 3. Percentage of Patients with ≥ 1 Health Complication by Polypharmacy and Body 
System during 2nd, 3rd, and 4th Quarters of the Year Following Incident Cancer Diagnosis for 
2011-2015 (N=8,891). 
 
  Breast (N=3,557) Prostate (N=3,683) Colorectal (N=1,035) Lung (N=616) 
HC Group No PP (%) PP (%) No PP (%) PP (%) No PP (%) PP (%) No PP (%) PP (%) 
ADE 2.2 4.1 0.7 1.4 1.6 2.9 2.6 4.4 
CNS 2.0 5.2 2.5 4.8 3.2 5.6 2.7 7.1 
CV 6.9 15.0 10.2 21.2 10.1 24.1 13.6 23.3 
GI* 1.2 2.2 1.4 2.8 4.1 5.5 2.6 3.0 
HEMA 6.6 11.6 3.9 6.3 7.2 12.6 9.5 16.4 
METB 0.5 2.7 1.3 4.0 2.4 6.7 2.9 6.0 
SKEL* 3.5 5.7 3.3 5.2 4.0 6.1 4.8 6.0 
ANY 18.0 32.5 18.2 32.5 24.1 40.9 28.2 42.9 
 Notes: HC= health complication; ADE= adverse drug event; CNS= central nervous system and 
psychiatric; CV= cardiovascular; GI= gastrointestinal; HEMA= hematologic; METB= metabolic; 
SKEL= skeletal. PP= polypharmacy. *= GI HCs for lung and colorectal differences between PP and no 
PP were not statistically significant (p-value 0.0556 and 0.7556, respectively), nor for SKEL (p-value 
0.3132). All remaining differences between PP and no PP for HC group by cancer type were significant 
(p-value < 0.05).  
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
No PP PP No PP PP No PP PP No PP PP
Breast (N=3,557) Prostate (N=3,683) Colorectal (N=1,035) Lung (N=616)
ADE CNS CV GI HEMA METB SKEL
118 
 
Figure 4. Adjusted Odds Ratios (aORs) with 95% Confidence Intervals of Significantly 
Associated Investigated Variables for ≥ 1 Health Complication, Results of a Multivariable 
Logistic Regression Model for Newly Diagnosed Adult (≥ 18 years) Cancer Patients in the US 
2011-2015 (N=35,336). 
 
  
 
Notes: *= not statistically different from reference group.  
Reference categories for the investigated variables above were as follows: No polypharmacy, Age 
group 50-64, Midwest region, prostate cancer, Elixhauser score of 0 (zero), not on radiation therapy 
(No), and not on chemotherapy (No).  
C-statistic for model was 0.66. 
 
  
1.31
1.00
0.88
1.39
1.08
0.98
0.86
0.83
0.84
1.23
0.92
1.54
1.07
1.06
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8
Polypharmacy (Yes)
Age group, 18-49*
Age group, 65-74
Age group, ≥75
Northeast
South*
West
Breast
Prostate
Lung
Elixhauser Score, 1-2
Elixhauser Score, ≥3
Chemotherapy (Yes)
Radiation (Yes)
119 
 
Table 3. Multivariable Logistic Regression Results of Adult (≥ 18 years) Patients with Cancer for 
Odds of having ≥ 1 Health Complication, by Type of Cancer, Adjusted Odds Ratios (aORs) with 
95% Confidence Intervals (95% CI). 
Investigated 
Variable 
  
Breast Prostate Colorectal Lung 
aORs (95% CI) aORs (95% CI) aORs (95% CI) aORs (95% CI) 
Polypharmacy (ref= No polypharmacy) 
Yes 1.37 (1.31 - 1.42) 1.27 (1.22 - 1.32) 1.26 (1.16 - 1.36) 1.25 (1.11 - 1.40) 
Sex (ref= Women) 
Men N/A N/A NS 1.22 (1.10 - 1.36) 
Age group (years), (ref= 50-64) 
18-49 1.14 (1.04 - 1.25) 0.65 (0.51 - 0.83) 0.61 (0.49 - 0.75) 1.66 (0.94 - 2.94) 
65-74 0.81 (0.76 - 0.87) 1.05 (0.96 - 1.16) 1.03 (0.89 - 1.18) 0.77 (0.61 - 0.98) 
≥ 75 1.26 (1.17 - 1.35) 1.71 (1.55 - 1.88) 1.73 (1.52 - 1.97) 1.04 (0.82 - 1.31) 
Region (ref= Midwest)  
Northeast 1.09 (0.99 - 1.21) 1.12 (1.02 - 1.23) 1.00 (0.83 - 1.20) NS 
South 1.05 (0.98 - 1.12) 0.91 (0.86 - 0.97) 1.07 (0.94 - 1.21) NS 
West 0.82 (0.77 - 0.88) 0.90 (0.84 - 0.97) 0.81 (0.71 - 0.93) NS 
Elixhauser Comorbidity Score (ref= 0)  
1-2 0.94 (0.89 - 0.99) 0.91 (0.86 - 0.96) 0.82 (0.74 - 0.92) 1.11 (0.95 - 1.31) 
≥ 3 1.40 (1.32 - 1.49) 1.70 (1.60 - 1.80) 1.54 (1.37 - 1.73) 1.69 (1.45 - 1.96) 
Chemotherapy (ref= not on treatment)   
On treatment NS NS 1.35 (1.21 - 1.50) 1.33 (1.15 - 1.54) 
Radiation (ref= not on treatment) 
On treatment 1.10 (1.05 – 1.15) NS NS 1.25 (1.10 - 1.36) 
Notes: Models were created for each type of cancer with health complications (HCs) as the 
dependent variable. HCs were dichotomized as absent (0) or present ≥ 1 (1).  
aORs in bold font indicate statistical significance where the 95% confidence interval did not cross 
1.0 at alpha < 0.05.   
NS = not significant during backward elimination modeling. Since each type of cancer was modeled 
separately, aORs for variables without statistical significance are not shown. 
N/A = not applicable to breast and prostate cancer models due to sex-specific inclusions. 
Model c-statistics by type of cancer were as follows: breast 0.65; prostate 0.67; colorectal 0.68; lung 
0.67. 
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APPENDIX A 
CANCER DIAGNOSES OF INTEREST FOR STUDY POPULATION 
Clinical Classification Codes [CCCODEX] of disease medical codes 
 
Diagnosis (type of cancer) CCCODEX 
Cancer of Head and Neck 11 
Cancer of esophagus 12 
Cancer of stomach 13 
Cancer of Colon 14 
Cancer of rectum and anus 15 
Cancer of liver and intrahepatic bile duct 16 
Cancer of pancreas 17 
Cancer of Other GI Organs, Peritoneum 18 
Cancer of Bronchus, Lung 19 
Cancer; other respiratory and intrathoracic 20 
Cancer of bone and connective tissue 21 
Melanomas of Skin 22 
Other Non-Epithelial Cancer of Skin* 23 
Cancer of Breast 24 
Cancer of Uterus 25 
Cancer of other Female Genital Organ 28 
Cancer of Prostate 29 
Cancer of Testis 30 
Cancer of Other Male Genital Organs 31 
Cancer of Bladder 32 
Cancer of kidney and renal pelvis 33 
Cancer of other urinary organs 34 
Cancer of brain and nervous system 35 
Cancer of thyroid 36 
Hodgkin`s disease 37 
Non-Hodgkin's Lymphoma 38 
Leukemias 39 
Multiple myeloma 40 
Cancer, Other and Unspecified Primary 41 
Secondary malignancies* 42 
Malignant Neoplasm Without Specification 43 
Neoplasms of Unspecified Nature or Unknown 44 
Benign neoplasm of uterus* 46 
Other and Unspecified Benign Neoplasm* 47 
* = Excluded from analysis; Codes are available at: 
https://meps.ahrq.gov/data_stats/download_data/pufs/h170/h170app3.html#Top 
121 
 
APPENDIX B 
PRIORITY CONDITIONS AND OTHER CONDITIONS INVESTIGATED 
Clinical classification codes [CCCODEX] and International Classification of Disease 9th 
Edition [ICD-9] medical codes 
 
 
 
 
 
 
 
 
 
Physicala 
Condition Source Code 
Arthritis (infective & osteomyelitis 201, rheumatoid 
arthritis 202, osteoarthritis 203, other non-traumatic joint 
disorders 204) CCCODEX 201-204 
Chronic Obstructive Pulmonary Disease (COPD) 
(chronic bronchitis 491, emphysema 492, Bronchiectasis 
(494), chronic airway obstruction 496), asthma 128,493 
CCCODEX 127, 128 
ICD9CODX 
491,492, 
493, 
494,496 
Diabetes (without complications 049, with complications 
050) CCCODEX 049, 050 
Heart conditions (acute myocardial infarction 100, 
coronary atherosclerosis 101, nonspecific chest pain 102, 
pulmonary heart disease 103, other heart disease 104, 
conduction disorders 105, cardiac dysrhythmias 106, cardiac 
arrest 107, congestive heart failure 108), stroke (hemiplegia 
342, cerebrovascular disease 430-438), hypertension 
(essential 098, with complications and secondary 099) 
CCCODEX 096-099 
ICD9CODX 
100-108, 
342, 430-
438 
 
Mentalb 
Mood Disorder (depression and bipolar) ICD9CODX 657 
Anxiety CCCODEX 651 
Notes: aPhysical chronic conditions were identified using the information provided by MEPS which 
can be found here: https://meps.ahrq.gov/mepsweb/data_stats/MEPS_topics.jsp. bMental conditions 
are also from MEPS and can be found here: https://www.hcup-
us.ahrq.gov/toolssoftware/ccs/AppendixCMultiDX.txt 
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APPENDIX C 
 
SETTINGS OF CARE CODES  
 
Medical Expenditures Settings of Care classification codes 
 
Setting of Care Expenditure Variable 
Office-based  OBVEXP[YY] 
Hospital Outpatient OPTEXP[YY] 
Emergency Room ERTEXP[YY] 
Inpatient Hospital Stays IPTEXP[YY] 
Prescription Medicines RXEXP[YY] 
Dental  DVTEXP[YY] 
Home Health Care HHHCXP[YY] 
Other Medical Expenses VISEXP[14], OTHEXP[YY] 
Note: [YY] represents the placeholder for the 2-digit year associated with the year of the Household 
Component file.  Example OBVEXP14 would be the office-based variable for the year 2014. 
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APPENDIX D 
PRIORITY CONDITIONS AND OTHER CONDITIONS INVESTIGATED 
Clinical classification codes [CCCODEX] and International Classification of 
Disease 9th Edition [ICD-9] medical codes 
Medical Condition ICD9CODX CCCODEX 
Congestive heart failure 398, 402, 404, 428 108 
Valvular disease 093, 394, 395, 396, 397, 424, 746 096 
Pulmonary circulation disorder 415, 416, 417 103 
Peripheral vascular disorders 440, 441, 442, 443, 444, 447, 449, 557 114 
Hypertension, uncomplicated 401, 642 098, 184 
Hypertension, complicated 401, 402, 403, 404, 405, 437, 642 099, 183, 184 
Paralysis 342, 343, 344, 438, 780 082 
Other neurological disorders 330, 331, 332, 333, 334, 335, 338, 340, 341, 
345, 347, 649, 768, 780, 784 
079, 080, 081 
Chronic pulmonary disease 490, 491, 492, 493, 494, 495, 496, 500, 501, 
502, 503, 504, 505, 506 
127, 128 
Diabetes, uncomplicated 249, 250, 648 049 
Diabetes, complicated 249, 250, 648 050 
Hypothyroidism 243, 244 048 
Renal failure 403, 404, 585, 586 157 
Liver disease 070, 456 150, 151 
Peptic ulcer disease, excluding bleeding 531, 532, 533, 534 139 
HIV/AIDS 042, 043, 044 005 
Rheumatoid arthritis 701, 710, 714, 720, 725 202 
Coagulation disorders 286, 287, 289, 649 062 
Obesity 278, 649, 793 N/A 
Weight loss 260, 261, 262, 263, 783 052 
Fluid and electrolyte disorders 276 055 
Anemia, blood loss* 280, 648 059 
Anemia, deficiency* 280, 281, 285 059 
Alcohol abuse 291, 303, 305 660 
Drug (substance) abuse 292, 304, 305. 648 661 
Psychoses 295, 296, 297, 298, 299 659 
Depression 300, 301, 309, 311 657 
Note: *= must have both ICD9CODX and CCCODEX codes. Due to inclusion/exclusion criteria for the cancer 
survivor population in the study, the Elixhauser coding for lymphoma, metastatic cancer, and solid tumors 
without metastasis are excluded as comorbid conditions. MEPS uses 3-digit ICD9CODX and CCCODEX codes.  
The search algorithm only counted a medical condition as present or absent, and no double-counting occurred if 
a patient had both the ICD9CODX and CCCODEX codes. If a survivor had both diabetes complicated and 
uncomplicated, preference was given to complicated. If a survivor had hypertension complicated and 
uncomplicated, preference was given to complicated. 
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APPENDIX E 
 
CANCER DIAGNOSES OF INTEREST FOR STUDY POPULATION 
International Classification of Diseases, 9th Revision, Clinical Modification Codes 
 
Cancer Type ICD-9-CM Abbreviated Codesa 
Breast 174.x, 198.81, 233.0  
Colon 
Rectum 
153.x, 197.5, 209.13, 209.14, 209.15, 209.16, 230.3 
154.x, 209.17, 230.42 
Prostate 185, 233.4 
Lung 162.2-162.9, 197.0, 231.2 
Note: Codes include carcinoma in situ and metastatic cancer.  
aHCUP CCS. Healthcare Cost and Utilization Project (HCUP). March 2017. Agency for 
Healthcare Research and Quality, Rockville, MD. www.hcup-
us.ahrq.gov/toolssoftware/ccs/ccs.jsp. 
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APPENDIX F 
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ) 
International Classification of Disease 9th Edition [ICD-9] medical codes for 
Elixhauser Comorbidity Score 
Medical Condition ICD-9-CM Code29 
Congestive heart failure 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 
404.13, 404.91, 404.93, 428.x 
Valvular disease 093.2, 394.x - 397.1, 397.9, 424.x, 746.3 - 746.6, V42.2, 
V43.3 
Pulmonary circulation disorder 416.x, 417.9 
Peripheral vascular disorders 440.x, 441.x, 442.x, 443.1 - 443.9, 447.1, 557.1, 557.9, V43.4 
Hypertension, uncomplicated 401.1, 401.9, 642.0 
Hypertension, complicated 401.0, 402.x - 405.x, 546.1, 642.1, 642.2, 642.7, 642.9 
Paralysis 342.x - 344.x, 438.2x - 438.5x 
Other neurological disorders 330.x - 331.x. 332.0, 333.4, 333.5, 334.x, 335.x, 340, 341.1-
341.9, 345.x, 347.x, 780.3, 784.3 
Chronic pulmonary disease 490x-492.x, 493.x, 494x - 505.x, 506.4 
Diabetes, uncomplicated 250.0 - 250.3, 648.0 
Diabetes, complicated 250.4 - 250.9, 775.1 
Hypothyroidism 243 - 244.2, 244.8, 244.9 
Renal failure 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 
404.92, 404.93, 585.x, 586.x, V42.0, V45.1, V56.x 
Liver disease 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 456.0, 456.1, 
456.20, 571.0, 571.2-571.9, 572.3, 572.8, V42.7 
Peptic ulcer disease, excluding bleeding 531.41, 531.51, 531.61, 531.7, 531.91, 532.41, 532.51, 532.61, 
532.7, 532.91, 533.41, 533.51, 533.61, 533.7, 533.91, 534.41, 
534.51, 534.61, 534.7, 534.91 
HIV/AIDS 042.x-044.x 
Rheumatoid arthritis 701.0, 710.x, 714.x, 720.x, 725.x 
Coagulation disorders 286.x, 287.1, 287.3-287.5 
Obesity 278.0 
Weight loss 260.x-263.x, 783.2 
Fluid and electrolyte disorders 276.x 
Anemia, blood loss* 280.0, 648.2 
Anemia, deficiency* 280.1-281.9, 285.2, 285.9 
Alcohol abuse 291.0-291.3, 291.5, 291.8, 291.9, 303.x, 305.0 
Drug (substance) abuse 292.0, 292.82-292.89, 292.9, 304.x, 305.2-305.9, 648.3 
Psychoses 295.x-298.x, 299.1 
Depression 300.4, 301.12, 309.0, 309.1, 311 
Note: Due to inclusion/exclusion criteria for the cancer patient population in the study, the Elixhauser 
coding for lymphoma, metastatic cancer, and solid tumors without metastasis are excluded as comorbid 
conditions. If a patient had both diabetes complicated and uncomplicated, preference was given to 
complicated. If a patient had hypertension complicated and uncomplicated, preference was given to 
complicated. 
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APPENDIX G 
RADIATION THERAPY CODES 
Current Procedural Terminology (CPT) and Healthcare Common Procedure 
Coding System (HCPCS) 
 
Description of Procedure Codes / Code Range Sourceb 
Therapeutic radiology: planning 77261-77263 CPT 
Radiation therapy simulation 77280-77299 CPT 
Radiation physics services 77300-77370 CPT 
Sterotactic radiosurgery 77371-77373 CPT 
Radiation treatment 77401-77417 CPT 
IMRT deliverya 77401-77417 CPT 
Steroscopic imaging guidance 77421 CPT 
Neutron therapy 77422-77423 CPT 
Radiation therapy management 77427-77499 CPT 
Proton therapy 77520-77525 CPT 
Hyperthermia treatment 77600-77620 CPT 
Brachytherapy 77750-77799 CPT 
Ultrasound localization of radiation therapy G6001 HCPCS 
Stereoscopic x-ray guidance G6002 HCPCS 
Radiation Treatment delivery G6003-G6017 HCPCS 
Notes: aIMRT = intensity modulated radiation therapy.  
bSources are listed as reference numbers 22 and 23 from manuscript 3. 
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APPENDIX H 
 
ADVERSE EVENT CODES 
Common Adverse Events and Drug-Related Events in Cancer Patients 
 
Category Adverse event ICD-9-CM  
Cardiovascular Conduction disorders;  
Cardiac arrhythmias;  
Tachycardia 
426.x,  
427.x;  
785.0 
Secondary hypertension and 
Hypertension complications; 
Hypotension 
405.x,  
 
458.x 
Central 
nervous system 
and psychiatric 
Seizures/convulsions (not epilepsy); 
Myoclonus 
780.3x;  
333.2 
Syncope/collapse/faint 780.2 
Delirium (acute, subacute),  
Drug psychoses 
293.0, 293.1;  
292.x 
Neuropathy due to drugs  357.6 
Gastrointestinal Acute gastrointestinal bleeding d531.0x, 531.1x, 531.3x, 532.0x, 
532.1x, 532.2x, 533.0x, 533.1x, 
533.2x, 534.0x, 534.1x, 534.2x, 
535.01, 535.11, 535.21, 535.41, 
535.51, 535.61, 535.71, 578.x 
Hematologic Pulmonary embolism or Venous 
thromboembolism; 
Anemia; 
Leukopenia; 
Neutropenia; 
Thrombocytopenia; 
415.1x, 451.x, 452.x, 453.x;  
 
280.x, 281.x, 285.2, 285.9, 648.2; 
288.50, 288.51, 288.59;  
288.00, 288.03, 288.09;  
287.3, 287.5, 289.84 
Metabolic Acute renal failure 584.x 
Skeletal Fracture a800.xx-829.xx, aE880-E887 
Dislocationf f830.xx-839.xx 
Intracranial injuryf f850.xx-854.xx 
Crushing injuryf f925.xx-929.xx 
Other head injuries (not included in 
fracture above) 
g870.xx–873.xx, 900.xx, 910.xx, 
918.xx, 920.xx-921.xx, 950.xx-
951.xx 
Other spinal injuries (not included in 
fracture above) 
g 846.xx-847.xx, 952.xx –954.xx 
Falls cV15.88 
Other Unspecified adverse effect of 
unspecified drug, medicinal and 
biological substance 
 
b995.0, 995.20, 995.4 
Poisonings by drugs, medicaments, 
and biological substances; and late 
effects 
g 960-977; 909.0, 909.5 
Toxic effects of substances g 980.xx-989.xx 
Adverse effects in therapeutic use of 
drugs, medicaments, and biologics 
g E930.xx -E949.xx 
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Notes: ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical 
Modification. 
a: Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from 
computerized Medicare files. J Clin Epidemiol. 1992;45(7):703–14.  https://doi-
org.uri.idm.oclc.org/10.1016/0895-4356(92)90047-Q. 
b: Certain health complications not classified elsewhere. ICD9DATA.com 
http://www.icd9data.com/2015/Volume1/800-999/990-995/995/default.htm  
c: Kim DH, Schneeweiss S. Measuring frailty using claims data for pharmacoepidemiologic 
studies of mortality in older adults: evidence and recommendations. Pharmacoepidemiology 
and drug safety. 2014;23(9):891-901. doi:10.1002/pds.3674. 
d: Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? 
Annals of Oncology 20: 1907–1912, 2009. doi:10.1093/annonc/mdp369. 
e: Tamariz et al. A systematic review of validated methods for identifying ventricular 
arrhythmias using administrative and claims data. Pharmacoepidemiology and drug safety 
2012; 21(S1): 148–153. Published online in Wiley Online Library (wileyonlinelibrary.com) 
doi: 10.1002/pds.2340   
f: Waters TM, Chandler AM, Mion LC, Daniels MJ, Kessler LA, et al. Use of International 
Classification of Disease, Ninth Revision, Clinical Modification, codes to identify inpatient 
fall-related injuries. J Am Geriatr Soc. 2013 Dec;61(12):2186-91. doi: 10.1111/jgs.12539. 
Epub 2013 Nov 1. 
g: Rassekh SR, Lorenzi M, Lee L, Devji S. Reclassification of ICD-9 Codes into meaningful 
categories for oncology survivorship research. J Cancer Epidemiol. 2010;2010:569517. doi: 
10.1155/2010/569517. Epub 2010 Dec 29. 
 
 
